Pass · 72/100 · medium confidence

RESMED INC (RMD) — Council Assessment

🟢 PASS · Score 72/100 · medium confidence

High-quality, net-cash CPAP franchise trading ~35% below peak at 17x FCF, with a credible-but-unquantified GLP-1 demand headwind as the swing factor.

As of 2026-07-27. 18 lenses weighed in, 0 abstained. Sources: 7 filings, 54 news, 26 discussion.

⚠️ Data integrity: Band moved Watch → Pass on an INCOMPLETE dataset — verify before acting; this may be a data artifact, not a real change. Gaps: 80 of 80 source documents were dropped to fit the prompt budget — the council did not see them.

360 narrative — news & sentiment digest

ResMed Inc. (RMD) — Investment Briefing

Recent Developments

MatrixCare sale announced (early July 2026): Needham maintained "Hold" rating on the news; this represents a divesting of a software/cloud asset.
Q4 FY2026 earnings scheduled for August 6, 2026 (as of late June).
Record free cash flow: FCF hit $1.7B as of late July, despite stock down ~30% from peak.
RBC Capital Markets downgrade (mid-July 2026): Notable negative call from sell-side.
Noctrix acquisition announced (mid-July); commentary mixed on strategic value.
Russell Growth Index removal (early July): Triggered some short-covering rally (+5.6%).
Insider selling: CEO sold ~5,000 shares after option exercise (June); counsel surrendered shares for RSU tax withholding (June).

Bull Narrative

Cash flow strength & valuation asymmetry:

Record $1.7B free cash flow signals operational resilience despite stock weakness (down 30% from peak).
Forward P/E ~19.6x vs. S&P 500 avg ~25.6x; multiple sources flag "undervaluation" (GuruFocus, Yahoo Finance, DirectorsTalk).
GuruFocus GF Score of 90 cited; dividend yield attractive on quality foundation.
Strong profitability and cash conversion noted by ChartMill.

Digital health & OSA expansion:

Positioned as "digital health pioneer scaling out-of-hospital software solutions" and sleep apnea (OSA) ecosystems (retail commentary).
Institutional options sweep activity observed on August $210–$220 calls, signaling smart-money bullish positioning.
Robust installed base of CPAP users provides recurring supply revenue moat.

M&A optionality:

Noctrix and MatrixCare transactions signal inorganic growth strategy; one source alludes to a "closed-loop triad" involving AbbVie board representation and trial monitoring (Incannex), though this is speculative.

Bear Narrative

Structural demand headwind from GLP-1 drugs:

Critical concern emerging in retail/independent analyst circles: If GLP-1 weight-loss medications reduce obesity prevalence, future sleep apnea incidence may decline, shrinking the patient funnel and long-term CPAP demand.
One analyst notes "the future patient funnel could be getting smaller," even if current installed base remains solid.

Clinical resistance to CPAP:

Retail posts state "People HATE CPAP" and warn of competitive threat from alternative devices (e.g., Apnimed); unless RMD pivots to non-CPAP solutions, it risks displacement within 5 years.

Recent equity actions & analyst downgrade:

CEO/insider selling post-exercise (June) and counsel RSU withholding suggest potential lack of conviction at higher levels.
RBC Capital Markets downgrade in mid-July signals institutional caution.

Valuation still elevated on weak growth:

Stock down 30% YTD but multiples (P/E 19.6x) still above many industrials; FCF strength may not translate to earnings growth if CPAP demand inflects.

M&A complexity:

MatrixCare sale dilutes software/cloud revenue stream; Noctrix acquisition rationale unclear to market (commentary mixed).

Management Commentary (Earnings Call)

No Q4 FY2026 earnings call transcript provided. The most recent available reference is a Q3 2026 call summary (April 2026), which did not yield specific quotes or guidance details in the materials.

Expected earnings date: August 6, 2026 — call may address:

GLP-1 headwind perception & patient funnel outlook
MatrixCare exit rationale & impact on software revenue
Noctrix strategic rationale & integration timeline
FY2027 guidance amid macro uncertainty

Retail Sentiment

Mixed to cautiously bullish, with emerging structural concerns:

Bullish camp focuses on cash flow fortress, options accumulation activity, and relative valuation. One trader cites "aggressive options accumulation" and "smart money" sweeps on August calls, interpreting this as a signal for "sharp trend expansion."
Bearish camp emphasizes the GLP-1 risk (novel, credible structural headwind) and CPAP obsolescence risk. Tone is urgent: "This company is dead until they make a move to expand beyond machines… a company like Apnimed will put them out of business within 5 years."
Neutral/quality-focused posts highlight dividend appeal and relative valuation vs. S&P 500, without strong conviction on near-term catalysts.

Overall conviction is low to moderate; debate centers on long-term demand sustainability rather than near-term earnings beats.

Caveats

No recent earnings call transcript: Unable to assess management's own framing of GLP-1 impact, MatrixCare rationale, or FY2027 outlook. August 6 call will be critical.
Retail sources (Twitter, forums) are speculative: Claims about "smart money sweeps," AbbVie/Incannex board maneuvers, and Apnimed competitive threat are inferences, not verified facts. Treat as color, not evidence.
GLP-1 headwind is emergent opinion, not yet quantified: No analyst reports or guidance from RMD management directly addressing obesity-driven demand deflation. This is a hypothetical structural risk gaining traction in discussion, not yet consensus.
Insider selling context limited: Stock down 30% YTD; insiders selling post-exercise may reflect tax optimization or routine diversification rather than loss of confidence.
Analyst coverage thin on recent downgrades: Only RBC mentioned; unclear if broader street is pivoting bearish or if this is isolated.
Valuation metrics mixed: While P/E 19.6x appears cheap vs. S&P, absolute FCF yield and forward EPS growth are not clearly stated in materials.

Next catalyst: Q4 FY2026 earnings (Aug 6) and management guidance on demand/margins post-GLP-1 wave.

Bull case

The quality-lens majority (Buffett, Munger, Akre, Terry Smith, Mauboussin, Greenblatt all 74-78) converge on a genuine franchise: ROIC ~18% vs. WACC ~8% (1000bps spread sustained for years), FCF margin expanded from 6% (FY22) to 32.3% (FY25), FCF of $1.66B exceeds net income of $1.40B (cash conversion >100%, the opposite of an accounting red flag), and a fortress balance sheet (net cash ~$338M, D/E 0.17, current ratio 3.06). The moat is concrete—~35-50% global CPAP share, a large installed base with recurring mask/supply revenue, and a proprietary connected-device data flywheel (AirView/myAir) that AI enhances rather than disrupts. The Damodaran referee (78, high) judges the DCF assumptions conservative: the 12% growth rate merely matches the 3-yr revenue CAGR while actual FCF CAGR was ~27%, and even the bear case ($249) sits 28% above the $195 price. The forensic short-seller (72) explicitly concludes 'this is not a short.'

Bear case

The stock is a broken tape—down ~30-34% from its $293.81 peak, sitting at/near its 52-week low, with an RBC downgrade and Russell Growth Index removal. The value/momentum lenses (Druckenmiller 52, Graham 52, Klarman 55, Lynch 58, Marks 55) all balk: at 20x P/E, 4.48x book, 5.5x sales and PEG 1.57 this is fair-not-cheap, failing Graham's combined-multiple test badly (P/E x P/B = 90.6 vs. 22.5 ceiling). Schloss avoids outright (22). The GLP-1 structural headwind is the pivotal, unresolved question—if obesity drugs shrink the OSA patient funnel over 5-10 years, it attacks the normalized earnings base, not just terminal growth. That matters because 80% of the DCF's intrinsic value is terminal value, and Greenwald's zero-growth EPV is only ~$98/share, meaning ~$97 of the current price is a growth premium that GLP-1 threatens. MatrixCare divestiture plus opaque Noctrix acquisition add M&A noise, and no Q4 FY26 transcript means management's own GLP-1 framing is unknown.

Dissent — where the council disagrees

The council splits cleanly along a quality-vs-price/momentum fault line. Nine quality/growth lenses plus both valuation referees pass at 72-78; four risk/value lenses (Graham, Klarman, Marks, Lynch) sit at Watch and Druckenmiller (52) flags a broken tape as a primary disqualifier. Schloss avoids at 22. The most decision-relevant dissent is threefold: (1) Druckenmiller's 'the tape is broken and estimate revisions point down—don't fight it' directly contradicts the value crowd's DCF upside; (2) Greenwald's EPV of ~$98 vs. price of $195 reframes the '65% upside' story as investors paying a large growth premium into a franchise whose runway GLP-1 puts in question—this undercuts the clean bull narrative; (3) even bullish lenses universally flag the 80% terminal-value dependence as the model's weak point. The tension that must be surfaced: this passes only if you trust normalized earnings durability, and the single biggest variable (GLP-1) is admittedly unquantified across ALL lenses.

Key risks

GLP-1 weight-loss drugs structurally shrinking the OSA patient funnel over 5-10 years—attacks the earnings base, not just terminal growth; unquantified by every lens
DCF/intrinsic value is 80% terminal value; Greenwald's zero-growth EPV (~$98) is far below price, meaning the thesis rests on a large, GLP-1-vulnerable growth premium
Broken price momentum (near 52-week low, -30% from peak), RBC downgrade, Russell Growth removal—no positive estimate-revision or liquidity tailwind
Capital-allocation ambiguity: MatrixCare divestiture removes recurring SaaS revenue while Noctrix acquisition rationale is unclear to the market
Information gap: no Q4 FY2026 earnings transcript, so management's GLP-1 assessment and FY2027 guidance are unknown ahead of the Aug 6 print
Fair-not-cheap on hard metrics (20x P/E, 4.48x P/B, 5.5x P/S, PEG 1.57)—limited margin of safety if growth decelerates

Catalysts

Q4 FY2026 earnings (Aug 6) providing management's quantified GLP-1 impact and FY2027 guidance—could re-rate estimates either direction
Clinical/real-world data showing GLP-1 adherence remains low (~50% discontinuation) and OSA incidence is not materially declining
Intelligent redeployment of MatrixCare sale proceeds (buybacks or accretive M&A)
Evidence Noctrix/neurostimulation captures GLP-1-resistant patients, expanding TAM into alternative modalities
Continued FCF-margin durability and international underpenetration driving above-model growth

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $321.64/share vs price $195.27 → +65% (bear $249.45 · base $321.64 · bull $392.36).

Step	Value
Base free cash flow	$1.7B
FCF growth (yrs 1-5)	12.0% (revenue CAGR)
WACC (β 0.755)	8.0%
Terminal growth	2.5%
PV of explicit FCF	$9.3B
PV of terminal (residual) value	$37.5B (80% of EV)
Enterprise value	$46.8B
less Net debt	$-338M
= Equity value	$47.1B
/ Shares (146M) = intrinsic/share	$321.64

Short-sell evaluation

🚫 AVOID SHORTING

This is a poor short despite decelerating growth optics and a rich-ish multiple. The forensic short-seller (72) is explicit that the earnings-quality screen fails the short case: FCF ($1.66B) exceeds net income ($1.40B), the balance sheet is net cash, and there is no debt wall, refinancing risk, or accounting manipulation. Even the bear-case DCF ($249) sits above the current $195 price, so the fundamental floor is above the market. The only credible short vector is the GLP-1 secular-demand story, but it is unquantified, slow-moving, and likely already partially priced after a ~30% drawdown. Shorting a net-cash, 32%-FCF-margin, high-ROIC compounder trading at 17x FCF on an as-yet-unproven multi-year thesis is negative asymmetry—you fight strong fundamentals while carrying open-ended upside risk into a possible upside earnings surprise or short-covering.

Pros (the short could work)

GLP-1 secular headwind could compress the OSA patient funnel and normalized earnings over 5-10 years, deflating an 80%-terminal-value valuation
Growth premium is large: Greenwald's zero-growth EPV ~$98 vs. $195 price—if growth stalls, substantial multiple compression is possible
Broken momentum, RBC downgrade, Russell Growth removal, and negative estimate-revision tone provide a bearish tape
Fair-not-cheap valuation (20x P/E, 5.5x P/S, PEG 1.57) leaves little room for error if Aug 6 guidance disappoints
M&A noise (MatrixCare sale + opaque Noctrix deal) and insider selling are soft governance/conviction negatives

Cons (what kills the short)

Fortress fundamentals: net cash ~$338M, D/E 0.17, current ratio 3.06, 32% FCF margin, ROIC ~18%—structurally hard to break
Earnings quality is high (FCF > net income); no accounting red flags to catalyze a de-rating
Even the bear-case DCF ($249) is above the current price—valuation floor works against the short
GLP-1 thesis is unquantified and slow-moving; OSA has non-obesity causes and GLP-1 adherence is poor (~50% discontinue)—likely partially priced already
Squeeze/covering risk demonstrated (Russell removal already triggered a +5.6% short-covering rally); potential upside earnings surprise on Aug 6
Buybacks, dividend, and prodigious FCF provide continuous support; unlimited downside asymmetry on a quality compounder makes this a specialist-only, unattractive short

Council scorecard

Lens	School	Stance	Score	Conf
Chuck Akre	quality	🟢 pass	78	medium
Warren Buffett	quality	🟢 pass	78	medium
Valuation Referee (Damodaran-style)	referee	🟢 pass	78	high
Charlie Munger	quality	🟢 pass	78	medium
Terry Smith (Fundsmith)	quality	🟢 pass	78	medium
Joel Greenblatt	value	🟢 pass	76	medium
Philip Fisher	growth	🟢 pass	74	medium
Bruce Greenwald	value	🟢 pass	74	medium
Michael Mauboussin	quality	🟢 pass	74	medium
Ray Dalio	risk	🟢 pass	72	medium
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟢 pass	72	medium
Peter Lynch	growth	🟡 watch	58	medium
Seth Klarman	value	🟡 watch	55	medium
Howard Marks	risk	🟡 watch	55	medium
Stanley Druckenmiller	risk	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	52	medium
Walter Schloss	value	🔴 avoid	22	high

Member reasoning

Chuck Akre — 🟢 pass · 78/100 · medium confidence

ResMed meets most of Akre's three-legged stool criteria convincingly but with two meaningful caveats that prevent a higher score. On the business quality leg: ROE of 22.2% and ROIC of 18.0% are achieved on a nearly debt-free balance sheet (D/E of 0.17, net cash position of ~$338M), confirming these are genuine economic returns, not leverage artifacts. FCF conversion is exceptional — $1.66B FCF on $5.15B revenue yields a 32.3% FCF margin, up from 6% in 2022 and 27.8% in 2024, demonstrating an improving capital-light franchise with real pricing power and switching costs embedded in its CPAP ecosystem (device + masks + cloud software + connected care data). Revenue CAGR of 12.9% over 3 years and net income nearly tripling from $474M (2021) to $1.4B (2025) confirms durable compounding. The FCF/share trajectory is what Akre cares about most — and it is sharply positive. On the reinvestment runway leg: this is the most contested leg. The installed base of CPAP users globally remains massively underpenetrated (estimated 80%+ of OSA patients undiagnosed/untreated worldwide), giving a long secular growth runway. However, the GLP-1 structural risk is a legitimate, if unquantified, headwind — if obesity prevalence declines meaningfully, the future patient funnel narrows. This doesn't break the thesis over a 5-year horizon given diagnosis rates, aging demographics, and international underpenetration, but it does cap the reinvestment ceiling vs. what it was 3 years ago. The MatrixCare divestiture is a capital allocation negative from Akre's lens — selling a software asset with recurring revenue characteristics signals either portfolio complexity/distraction or that management overpaid originally; the Noctrix acquisition rationale is unclear. The capital allocation record is mixed: returning capital via buybacks and dividends while growing FCF is positive, but M&A track record needs watching. On the management/integrity leg: no accounting red flags, clean balance sheet, transparent SEC filings. Insider selling post-option exercise is routine and not alarming at this level. RBC downgrade and Russell index removal are near-term noise. On valuation: P/FCF of 17.1x and P/E of 20.2x are reasonable, not cheap, for a 12-13% grower with 32% FCF margins. The DCF base case at $321 implies 64.7% upside, which looks compelling, though the 80% terminal value weighting means the model is sensitive to assumptions about whether the GLP-1 headwind crimps the long-run growth rate. At 12% FCF growth assumed vs. the historical CAGR, the model is defensible but not conservative. Bear case of $249 still implies 27% upside from $195, providing reasonable margin of safety. AI/disruption: AI is likely a tailwind for RMD, not a threat — its AirView cloud platform and connected device data create a proprietary dataset and AI-enabled patient management capability that strengthens switching costs and provides a software moat around the hardware franchise. AI could enhance diagnosis, adherence monitoring, and telemetry, all of which ResMed is positioned to monetize rather than be displaced by. Overall, RMD scores high on business quality and moderate-to-high on runway, with a watch flag on management capital allocation and the GLP-1 structural risk requiring monitoring.

Key points

ROE 22.2% and ROIC 18.0% achieved on a near-debt-free balance sheet (D/E 0.17, net cash) — genuine business economics, not leverage
FCF margin expanded to 32.3% in FY2025 from 6% in FY2022; FCF of $1.66B on $5.15B revenue demonstrates capital-light franchise with real compounding power
Revenue 3-yr CAGR of 12.9%, net income $474M→$1.4B (2021–2025): per-share free cash flow compounding is exactly what Akre rewards
Global OSA underpenetration (~80% undiagnosed) provides a genuinely long reinvestment runway despite GLP-1 headwind concerns
DCF base case $321 (+65% upside) with bear case $249 (+27%) offers reasonable margin of safety at P/FCF 17.1x for the quality level
AI/cloud connectivity (AirView platform) strengthens rather than threatens the moat — proprietary adherence data and software switching costs are AI-enabled advantages

Red flags

GLP-1 structural headwind: if obesity prevalence declines materially, future patient funnel shrinks — unquantified but credible risk to the reinvestment runway thesis
MatrixCare divestiture removes a recurring software revenue stream; signals potential capital allocation inconsistency or prior M&A misjudgment
Noctrix acquisition rationale unclear to market; adds execution risk and potential empire-building concern if not clearly value-accretive
80% of DCF value sits in terminal value — model is highly sensitive to long-run growth rate assumptions that GLP-1 could impair
RBC downgrade and mixed sell-side sentiment suggest institutional caution; no FY2027 guidance visibility ahead of Aug 6 earnings

Warren Buffett — 🟢 pass · 78/100 · medium confidence

ResMed fits squarely within the Buffett quality framework. It is a dominant, profitable, cash-generative business with an identifiable moat, consistent returns on capital, and a conservative balance sheet — all without heroic leverage. The core economics are understandable: ResMed sells CPAP devices and masks to sleep apnea patients (a large, underdiagnosed chronic condition), creates switching costs through its connected device ecosystem and physician relationships, and generates recurring supply revenue from masks/accessories. The numbers are compelling: 32.3% FCF margin (up from 6% in FY2022), ROE of 22%, ROIC of 18%, debt-to-equity of just 0.17, current ratio of 3.1, and $1.66B of free cash flow on $5.15B of revenue. Revenue CAGR of ~13% over 3 years is real, not accounting-driven. The DCF intrinsic value of ~$321/share vs. current price of $195 implies a 65% upside and a meaningful margin of safety — unusual for a quality compounder. At 17x price-to-FCF and 20x P/E, this is not cheap by absolute standards, but for a business of this quality with this growth rate, it is a fair-to-attractive price. The PEG of 1.57 is reasonable. The owner earnings picture is excellent: capex of only $90M against $1.75B operating cash flow means maintenance capex consumes less than 6% of OCF — this is the opposite of a capital-intensive treadmill. Balance sheet is fortress-like: $1.4B cash, $1.1B long-term debt, $6.3B equity. The primary risk is the GLP-1 structural headwind — if weight-loss drugs materially reduce OSA incidence over a decade, the patient funnel narrows. This is real but likely overstated in the near term: OSA is not purely obesity-driven (anatomy, genetics matter), the installed base creates multi-year recurring revenue, and the 1+ billion estimated undiagnosed OSA patients globally provide a long runway. The Noctrix acquisition and Mattrixcare divestiture suggest management is actively reshaping the portfolio, which introduces some capital allocation uncertainty. Insider selling is minor and likely routine. AI/tech disruption risk is low-to-moderate: ResMed's connected device platform and data moat (100M+ patients on cloud) actually positions it to leverage AI for adherence, diagnostics, and physician workflow — this is an enhancer, not a disruptor, for the franchise. Overall: a high-quality compounder at a below-fair-value price, with a credible but not existential structural risk that bears watching.

Key points

FCF margin expanded dramatically to 32.3% in FY2025 from 6% in FY2022 — demonstrates genuine operating leverage and pricing power, not just revenue growth
ROIC of 18% and ROE of 22% sustained WITHOUT heavy leverage (D/E only 0.17) — the hallmark of a genuine quality business
Capex of $90M vs. $1.75B operating cash flow means the business self-funds growth with minimal reinvestment — owner earnings are real
DCF intrinsic value ~$321/share vs. $195 current price implies 65% upside and a margin of safety rare for a quality compounder of this caliber
Conservative balance sheet: $1.4B cash, $1.1B long-term debt, 3.1 current ratio — can self-fund through any reasonable downturn
Revenue CAGR of 13% over 3 years is durable and broad-based across sleep/breathing and software segments
Connected device ecosystem with 100M+ cloud-connected patients creates switching costs and data moat that reinforce the competitive position
Low beta (0.76) consistent with defensive, recurring-revenue characteristics Buffett values

Red flags

GLP-1 structural risk is the most important long-term concern — if obesity drugs significantly reduce OSA incidence, the new patient funnel could contract over a 5-10 year horizon, even if the installed base remains durable
MatrixCare divestiture reduces recurring software revenue; combined with Noctrix acquisition, capital allocation rationale is unclear and bears scrutiny before the August 6 earnings call
CEO insider selling post-option exercise (June 2026) and RBC downgrade introduce modest near-term uncertainty, though context suggests routine rather than alarming
Residual value in DCF is 80% terminal value — heavily back-loaded, meaning the margin of safety depends significantly on long-term growth assumptions holding; if GLP-1 headwind materializes, terminal growth rate assumption of 2.5% may be optimistic
CPAP compliance/patient preference risk (retail commentary on 'people hate CPAP') is real but mitigated by lack of broadly approved alternatives today; Apnimed and others are speculative, not proven threats

Valuation Referee (Damodaran-style) — 🟢 pass · 78/100 · high confidence

ResMed presents a compelling Damodaran-style valuation case. The two-stage DCF embedded in the fact base yields an intrinsic value of $321.64/share versus a current price of $195.27, representing ~65% upside. Critically, the assumptions underlying that DCF are not heroic — a 12% FCF growth rate anchored to the actual 3-year revenue CAGR of 12.9%, a WACC of 7.96% (beta 0.755, a genuinely low-risk, recurring-revenue medical device business), and a 2.5% terminal growth rate that sits below the risk-free rate vicinity, all appear defensible. The bear-case intrinsic value is $249.45 — still 28% above the current price — meaning the stock looks cheap even under a pessimistic scenario. This is the core of the Damodaran margin-of-safety test: you do not need the optimistic case to win. The reverse-engineered implied expectations at $195.27 are modest: the market appears to be pricing in near-zero or low-single-digit perpetual growth, heavily discounted by GLP-1 fear. The fundamentals contradict this panic: FY2025 FCF of $1.66B on $5.15B revenue (32.3% FCF margin, up from 27.8% in FY2024 and 19.8% in FY2021), operating margin of 32.75%, net margin 27.2%, ROIC of 18% vs. WACC of ~8% — this is a company earning substantial economic profit with a wide spread. FCF grew from $634M in FY2021 to $1.66B in FY2025, a ~27% CAGR, well above the 12% assumed in the DCF. Reinvestment is capital-light (capex only $90M on $1.66B FCF, sales-to-capital ratio extremely high), consistent with a software-augmented medical device franchise — the growth story and the reinvestment story are internally consistent. Debt-to-equity of 0.17 with $1.42B cash and net cash position (-$338M net debt) means financial risk is minimal, supporting the low WACC. The primary risk — GLP-1 drugs reducing OSA incidence over a 5-10 year horizon — is real but currently unquantified and likely overstated in the current price. Even a moderate scenario where the TAM grows more slowly still supports substantial intrinsic value given current margins and reinvestment efficiency. The MatrixCare divestiture slightly reduces the software revenue stream but improves capital focus. AI/automation risk: RMD's Airsense platform and connected health data represent AI enhancement opportunity (remote monitoring, adherence algorithms) rather than pure commoditization risk — the hardware-software bundle is not easily replicated by a pure AI entrant. The one genuine caveat: the 80.1% terminal value weighting in the DCF is high, meaning the valuation is sensitive to the perpetuity assumption. At a 3% terminal growth rate instead of 2.5%, value rises materially; conversely at a higher WACC the terminal value declines meaningfully. But even stress-testing WACC to 9-10% would still yield intrinsic values above current price given the strong near-term cash generation.

Key points

DCF intrinsic value $321.64 vs. $195.27 price; bear-case $249.45 still 28% above current price — margin of safety holds even under pessimism
FCF margin expanded from 19.8% (FY2021) to 32.3% (FY2025); FCF CAGR ~27% over 4 years vs. only 12% assumed in model — DCF assumptions are conservative relative to recent history
ROIC 18% vs. WACC ~8% = 1000bps positive spread; growth genuinely creates value; reinvestment is capital-light (capex $90M vs. $1.66B FCF) — story-to-numbers internally consistent
Reverse-engineered market price implies GLP-1 fear is pricing in near-stagnation; current FCF run-rate alone implies P/FCF of 17x, cheap for a compounding franchise
Net cash position ($338M net cash), current ratio 3.06x, D/E 0.17 — balance sheet risk negligible, WACC of 7.96% is defensible, not artificially suppressed
Terminal value is 80% of enterprise value — standard sensitivity risk, but bear-case $249 already accounts for this; terminal growth 2.5% is below nominal GDP, not aggressive
AI/digital health position (Airsense connected platform) is enhancing, not threatening — remote adherence monitoring is a defensible, AI-augmented recurring revenue stream

Red flags

High terminal value weighting (80.1%) means the thesis is sensitive to discount rate shifts — a 150bps WACC increase would materially compress intrinsic value, though likely still above current price
GLP-1 structural demand risk is a legitimate long-term TAM headwind not fully reflected in the 12% perpetual growth assumptions — if revenue CAGR fades to 5-6% post-2027, the base case weakens
MatrixCare divestiture reduces software/SaaS revenue mix, slightly increases hardware cyclicality and commoditization exposure
No Q4 FY2026 earnings transcript available; management's own framing of GLP-1 impact and FY2027 guidance unknown — creates near-term uncertainty around the growth input
Insider selling post-option exercise and RBC downgrade are weak negative signals; not conclusive but worth monitoring for narrative inflection

Charlie Munger — 🟢 pass · 78/100 · medium confidence

ResMed is a genuinely great business sitting at a fair-to-attractive price — exactly the Munger sweet spot. The company dominates the global CPAP/sleep apnea device market with an estimated 50%+ share, a deeply entrenched installed base of ~10 million active therapy users generating recurring mask/supply revenue, proprietary cloud-connected platform (AirView/myAir) with 20+ billion nights of sleep data creating a near-irreplicable clinical data moat, and FDA regulatory barriers that take years and hundreds of millions to surmount. These are real, durable switching costs. The unit economics are simple enough to explain in a paragraph: sell a device, lock in the patient on consumable supplies and software monitoring for years, collect high-margin recurring revenue. ROIC of 18%, ROE of 22%, operating margin of 33%, and FCF margin of 32% — all sustained and rising — are the fingerprints of a business with genuine pricing power. FCF of $1.66B on $5.15B revenue, growing steadily from $634M in 2021, is exactly the kind of owner-earnings compounding Munger prizes. Debt-to-equity of 0.17 and a current ratio above 3x mean this balance sheet will survive a storm. The DCF intrinsic value of ~$322/share versus a current price of ~$195 implies a 65% upside, placing the stock well below even the bear-case DCF of $249. At P/FCF of 17x and P/E of 20x for a business compounding FCF at 12%+ with a defensible moat, this is a fair-to-cheap price for a wonderful business — not a cigar butt. The central risks are real but manageable through the Munger lens: GLP-1 drugs may reduce future OSA incidence at the margin, but (1) existing installed base is enormous and untreated OSA prevalence globally remains vast, (2) RMD has begun diversifying into non-obesity-driven respiratory disease and residential care software, and (3) GLP-1 adherence rates are poor, limiting the actual reduction in the patient funnel. The MatrixCare sale reduces software complexity. The Noctrix acquisition (neurostimulation for OSA) shows management is aware of the CPAP-alternative threat and acting on it. Insider selling is modest and routine post-exercise. Management's capital allocation record — R&D investment, disciplined acquisitions, buybacks — is rational. The one note of caution: the narrative uncertainty around GLP-1 and competitive alternatives (Apnimed, oral therapies) introduces a long-duration structural question that honest Munger analysis cannot dismiss. I cannot be fully confident the moat is impregnable over a 10-year horizon. This prevents a score above 80. But I see no obvious path to permanent capital impairment: balance sheet is clean, cash generation is prodigious, and the business is not standing still. On inversion — how does this go to zero? Only if GLP-1 drugs actually cure OSA broadly AND competitors displace CPAP before RMD can pivot AND regulators block RMD from entering new modalities. That chain of conjunctions is not impossible but is far from base case. AI is a net positive here: RMD's data asset (20B+ nights) and connected-device platform are strengthened, not threatened, by AI-driven diagnostics and care management. A competitor trying to replicate that proprietary longitudinal dataset would face enormous time and cost barriers.

Key points

Dominant market position (~50%+ global CPAP share) with massive, entrenched installed base generating recurring consumable and software revenue — textbook switching cost moat
Exceptional financial quality: 33% operating margin, 32% FCF margin, 18% ROIC, 22% ROE — all sustained and improving over 4+ years
FCF grew from $634M (2021) to $1.66B (2025), a 27% CAGR — owner earnings compounding at high incremental returns exactly as Munger would want
Clean balance sheet: D/E 0.17, current ratio 3.06, net cash position after accounting for debt — survives any plausible downturn without capital impairment
Fair entry price: P/FCF 17x, P/E 20x for a moat business at DCF intrinsic value ~$322 — a meaningful margin of safety even under bear assumptions ($249)
Simple, understandable model: device + recurring supplies + cloud monitoring subscription — predictable unit economics, inside the circle of competence
AI/data asset is a durable advantage: 20B+ nights of proprietary sleep data are irreplicable and enhance clinical value proposition, not a disruption target
Management rational on capital allocation; M&A (Noctrix) signals awareness of CPAP-alternative risk and proactive diversification

Red flags

GLP-1 structural demand headwind is a credible long-term risk to the patient funnel — not yet quantified but cannot be dismissed; bears a legitimate case that future OSA incidence may decline meaningfully over a decade
CPAP-alternative competitive threat (oral pharmacotherapy, neurostimulation) could erode the device moat if adoption accelerates; RMD's Noctrix acquisition is a hedge but integration risk is real
MatrixCare divestiture removes a software revenue stream; overall software/SaaS portion of business shrinks, reducing diversification away from hardware
RBC downgrade and absence of Q4 FY2026 earnings call transcript mean current sell-side sentiment and management guidance on GLP-1/margins are opaque — information gap at a critical juncture
Insider selling by CEO post-exercise, while routine, is a mild negative signal at a price well below the 52-week high of $293
DCF is highly sensitive to terminal growth assumptions — 80% of value in terminal value; any sustained growth deceleration below model assumptions significantly compresses intrinsic value

Terry Smith (Fundsmith) — 🟢 pass · 78/100 · medium confidence

ResMed passes the core Fundsmith quality checklist convincingly on capital returns, margins, cash conversion, and capital intensity. The business earns an ROCE of roughly 18-22% (ROIC reported at 18%), operating margins of 32.8%, FCF margins of 32.3%, and cash conversion that is exemplary — FCF of $1.66B closely tracks net income of $1.40B, implying a cash conversion ratio above 100%. The balance sheet is extremely clean: debt-to-equity of 0.17, current ratio of 3.06, net cash position of ~$338M (long-term debt ~$1.08B vs. cash ~$1.42B). Capital intensity is minimal — capex of only $90M on $5.15B revenue (capex/revenue ~1.7%), which is exactly the asset-light profile Smith prizes. Revenue has compounded at 12.9% over three years with steadily expanding margins (FCF margin expanded from 6% in 2022 to 32% in 2025, though the 2022 dip reflected one-off supply disruption costs). The moat rests on switching costs in the installed CPAP/flow-generator base, consumables recurrence (masks, tubing), cloud-connected device ecosystems, and now software infrastructure. These are genuine Fundsmith-grade moat attributes. Valuation is reasonable but not cheap: P/FCF of 17.05x, P/E of 20.2x, earnings yield of 6.0% — against a DCF intrinsic value of ~$322 per share (64.7% upside at base case). For a quality compounder this is a fair-to-attractive entry level. The main deductions from a perfect score are: (1) the GLP-1 structural demand risk is genuinely novel and credible — obesity is the primary OSA driver, and if GLP-1 prevalence durably shrinks the patient funnel, it directly attacks the long-term reinvestment runway that makes Fundsmith-style compounding work; (2) the Noctrix acquisition and the ongoing M&A pattern (MatrixCare buy/sell cycle) introduce mild serial-acquirer concern; (3) ROCE at ~18-20% is good but sits at the lower boundary of Smith's preferred 20%+ threshold; (4) the RBC downgrade and near-term absence of FY2027 guidance adds uncertainty. AI and digital disruption are actually a modest positive for RMD: its cloud-connected device platform (myAir, AirView) and data analytics moat are enhanced by AI-driven adherence coaching and remote monitoring — AI is more likely to reinforce the switching-cost moat than disintermediate it, as the proprietary patient data flywheel deepens over time. Net: a high-quality business at a fair price with one genuine structural headwind worth monitoring.

Key points

FCF of $1.66B exceeds net income of $1.40B — cash conversion >100%, Smith's core test passed
Operating margin 32.8%, FCF margin 32.3% — durable, high-quality margins with pricing power
Capex/revenue ~1.7% ($90M on $5.15B) — extremely asset-light, grows without capital intensity
Balance sheet very clean: D/E 0.17, net cash positive, current ratio 3.06
Revenue CAGR 12.9% over 3 years with margin expansion — compounding at above-average rates
P/FCF 17.05x, DCF intrinsic ~$322 vs. price ~$195 — meaningful margin of safety at base case
CPAP consumables (masks, tubing) create recurring purchase dynamics analogous to razor/blade model
Cloud-connected device data platform (myAir, AirView) creates switching costs and data moat that AI enhances rather than disrupts

Red flags

GLP-1 weight-loss drugs are a credible long-term structural threat to the OSA patient funnel — this is the single most important risk and not yet quantified
Noctrix acquisition rationale unclear; MatrixCare buy-then-sell cycle raises mild serial-M&A concern — Smith distrusts acquisitive complexity
ROIC of ~18% sits at the lower boundary of Smith's 20%+ preferred threshold, reducing the compounding quality premium
RBC Capital Markets downgrade in mid-July 2026 with no offsetting management guidance (Q4 earnings not yet released as of assessment date)
CEO insider selling post-option exercise (June 2026) — context suggests routine diversification but warrants monitoring
FCF history was volatile (2022: 6% margin) — though explained by Philips recall supply windfall reversal, it shows operating leverage can cut both ways

Joel Greenblatt — 🟢 pass · 76/100 · medium confidence

ResMed scores well on both axes of the Magic Formula. On the quality side (ROIC), the business earns exceptional returns on tangible capital: EBIT of ~$1.685B on a capital base of net working capital (current assets $3.82B minus current liabilities $1.25B = ~$2.57B NWC) plus net fixed assets (capex of only $90M signals asset-light manufacturing; PP&E likely modest relative to total assets of $8.5B which are dominated by intangibles/goodwill from acquisitions). Using a rough tangible capital estimate — even if I generously include $1B of net fixed assets — EBIT/tangible capital exceeds 40-50%, a genuinely high-quality business by Magic Formula standards. The FCF conversion is superb: $1.66B FCF on $1.69B EBIT yields a near-100% cash conversion ratio, confirming that the EBIT is real and not an accrual mirage. On the earnings yield side: EV = market cap ($28.3B) + long-term debt ($1.08B) - excess cash ($1.42B) = ~$28.0B. EBIT/EV = $1.685B / $28.0B = ~6.0%. That is a solid earnings yield for a high-quality compounder — not screaming cheap, but meaningful at a P/E of ~20x with 12-13% revenue CAGR. The combination of a 40-50%+ ROIC business at a ~6% earnings yield is above-average on the Magic Formula screen. The DCF intrinsic value of $321/share implies ~65% upside, and even the bear case ($249) is above today's price ($195). The MatrixCare sale is a mild special-situation catalyst — simplifying the business and likely returning capital. Key concerns: (1) GLP-1 headwind is a genuine long-term demand question for OSA patient volumes — Greenblatt would want to stress-test normalized EBIT if the patient funnel shrinks 10-20%; (2) the 52-week high data in fundamentals shows a range of $180-$294 (note: the price data shows conflicting 52W high figures — $209.63 vs fundamentals $293.81 — suggesting the stock has meaningfully derated, which adds some margin of safety); (3) long-term debt figure of $1.08B appears dated (labeled 2017-06-30 in filings), raising uncertainty about current net debt — though current assets of $3.82B vs total liabilities of $2.18B suggests a strong balance sheet regardless. AI risk is net positive for ResMed: its connected device platform (AirView, myAir) and cloud data moat become more valuable as AI-enhanced sleep scoring and remote monitoring deepen physician dependency on RMD's ecosystem. AI does not commoditize the hardware or reimbursement relationships. The RBC downgrade and GLP-1 noise have likely created short-term selling pressure that the Magic Formula investor should exploit rather than fear — the business quality is intact and the price has come in materially from peak.

Key points

EBIT/EV earnings yield ~6.0% on $28B EV — decent for a quality healthcare compounder
ROIC on tangible capital likely 40-50%+ given asset-light model (capex only $90M on $5.1B revenue)
FCF conversion near 100% ($1.66B FCF vs $1.69B EBIT) confirms EBIT is real, not accounting fiction
DCF intrinsic value $321/share vs $195 current price = 65% upside; bear case $249 still above market
Revenue CAGR 12.9% over 3 years; net margin 27.2%; operating margin 32.8% — genuinely excellent economics
Balance sheet fortress: current ratio 3.1x, debt/equity only 0.17x, $1.42B cash
MatrixCare sale is a mild simplification catalyst; Noctrix acquisition optionality in non-CPAP OSA treatment
AI enhances rather than threatens: connected device data moat deepens with AI-driven sleep analytics

Red flags

Long-term debt figure labeled 2017 in filings — actual current debt load requires verification from latest 10-Q
GLP-1 drugs represent a credible long-term demand headwind that could compress normalized EBIT if OSA incidence declines
At $195/share the earnings yield (~6%) is adequate but not deeply cheap — Magic Formula works best with higher earnings yields (7-10%+)
RBC downgrade and CEO insider selling (post-option exercise) add near-term sentiment uncertainty
Significant goodwill/intangibles from acquisitions inflate total assets; tangible capital estimate requires careful stripping of intangibles to confirm true ROIC
52-week high data inconsistency between price block ($209.63) and fundamentals block ($293.81) — confirm current price is genuinely near 52W lows

Philip Fisher — 🟢 pass · 74/100 · medium confidence

ResMed passes the Fisher growth lens with meaningful qualifications. The company demonstrates sustained organic revenue growth (12.9% 3-year CAGR to $5.15B in FY2025), exceptional and improving FCF conversion (32.3% FCF margin in FY2025 vs. 19.8% in FY2021), an expanding digital health/software layer alongside its core sleep-and-breathing hardware franchise, and management that appears to invest in R&D and product extension (Noctrix acquisition, residential care software segment). Operating margin of 32.8% and net margin of 27.2% are best-in-class for a medtech/health care device company. The two-stage DCF suggests ~65% upside to intrinsic value ($321.64 vs. $195.27), with a bear-case floor of $249.45, implying limited downside even on conservative assumptions. However, Fisher's bar for conviction requires visibility into a long multi-year growth runway, and the GLP-1 structural headwind introduces genuine uncertainty about the future patient funnel — this is the critical question Fisher would probe via scuttlebutt. The MatrixCare divestiture reduces the software/cloud revenue diversification story. No Q4 FY2026 earnings call transcript is available, limiting assessment of management candor and forward framing. Insider selling post-option exercise is not alarming but warrants monitoring. AI/digital disruption is more opportunity than threat here: ResMed's cloud-connected device ecosystem and proprietary patient data (AirSense/myAir platform) create a data moat that AI can deepen, not commoditize. The real disruption risk is pharmacological (GLP-1), not technological.

Key points

Revenue CAGR of 12.9% over 3 years to $5.15B demonstrates sustained above-industry organic growth consistent with Fisher Point 1
FCF margin expanded dramatically from 6% in FY2022 to 32.3% in FY2025, signaling genuine operating leverage and disciplined cost management
Operating margin of 32.8% reflects superior competitive position and pricing power in a regulated, clinician-endorsed category
Two-segment structure (Sleep & Breathing Health + Residential Care Software) shows management is building adjacencies beyond the core hardware cycle — Fisher rewards this long-range reinvestment orientation
Low beta (0.755) and low debt-to-equity (0.17) with $1.4B cash provide balance sheet optionality for organic R&D and selective M&A
ROIC of 18% with a P/FCF of 17x represents a reasonable entry point for a compounding business of this quality
Connected device ecosystem (AirSense + myAir) creates proprietary data assets that AI can deepen into adherence optimization and clinical analytics — a durable moat enhancement, not a disruption vector
DCF intrinsic value of $321.64 with bear-case $249.45 suggests asymmetric upside, reinforcing Fisher's buy-and-hold thesis at current prices

Red flags

GLP-1 drugs (Wegovy, Ozempic) represent a genuine structural headwind to future OSA patient incidence — Fisher would demand direct management commentary on this (not yet available; critical to assess at Aug 6 earnings call)
MatrixCare divestiture reduces software revenue diversification and raises questions about strategic clarity — was this a pruning of underperforming assets or a retreat from a stated growth strategy?
No earnings call transcript available; cannot apply Fisher's candor test (Points 14/15) to management's handling of difficult GLP-1 questions
Noctrix acquisition rationale is unclear to the market; mixed commentary suggests management has not yet told a compelling story — potential promotional or communications deficit
RBC Capital Markets downgrade in mid-July 2026 and stock trading ~34% below 52-week high of $293.81 suggest institutional confidence has eroded beyond what fundamentals alone explain
Revenue growth, while solid at 12.9%, is moderating from a higher post-Philips-recall surge; Fisher would need to see evidence that normalized growth runway remains 10%+ organically without the tailwind of competitor disruption

Bruce Greenwald — 🟢 pass · 74/100 · medium confidence

ResMed passes a Greenwald EPV/moat test with moderate conviction. Working through the framework: (1) EPV calculation — FY2025 operating income is $1,685M on $5,146M revenue (32.8% margin). This is arguably above-normalized; using a slightly more conservative 30% margin gives ~$1,544M EBIT. Tax-affecting at ~27% effective rate yields NOPAT of ~$1,127M. Maintenance capex is minimal ($90M capex vs. likely higher D&A, so no add-back needed; if anything a slight negative adjustment). Adding back excess D&A is not material here given the asset-light model. Capitalizing $1,127M at WACC of ~8%: EPV ≈ $14.1B. Adding net cash (~$338M) gives equity EPV ≈ $14.4B, or roughly $98/share. That is well below the current price of $195. However, this EPV is deliberately zero-growth. (2) The moat test is critical: EPV well above asset reproduction value signals a franchise. Tangible assets (stockholders' equity ~$6.3B, less goodwill/intangibles which are probably substantial for a medtech/software company) are significantly less than EPV. The gap is large and real — RMD earns ROIC of ~18% vs. WACC ~8%, a spread that has persisted across the cycle. This is the EPV >> reproduction value signal that Greenwald associates with a genuine franchise. The moat sources are concrete: (a) customer captivity — CPAP compliance data is cloud-integrated, patients are prescribed RMD devices via physician channels, switching is regulated and habitual; (b) scale economics in sleep diagnostics and connected device manufacturing; (c) 30+ year installed base with recurring mask/supply revenue. (3) So the correct framing is: this is a franchise, EPV understates value because growth inside a moat IS value-creating. The question is how much growth premium is justified. Current price of $195 implies a P/FCF of ~17x and P/E of ~20x on already-elevated margins, which embeds modest but real growth expectations. FCF has compounded from $634M (FY2021) to $1,662M (FY2025) — a ~27% 4-year CAGR — with margin expansion from 20% to 32%. This is not a growth-at-any-price valuation; the market is pricing in continuation of current earnings with limited additional growth. (4) GLP-1 risk is the most important Greenwald-relevant uncertainty. If obesity-driven OSA incidence declines structurally, the addressable patient funnel shrinks and EPV itself — not just growth — is at risk. This is NOT merely a DCF terminal-value risk; it threatens the normalized earnings base. However, OSA is only 50-60% obesity-related; RMD also addresses non-obese patients, children, and other respiratory conditions. The structural impairment is real but unlikely to be catastrophic. (5) MatrixCare sale reduces software revenue contribution but clarifies the core business — actually a positive for EPV clarity. (6) Concerns: the gap between EPV (~$98/share at zero growth) and current price (~$195) means investors are paying a ~$97/share growth premium. For a Greenwald purist, this is uncomfortable even in a franchise, because it requires ~8-10 years of above-WACC growth to close. The RBC downgrade and GLP-1 headwind suggest this premium deserves scrutiny. Margin of safety is thin by strict EPV standards. I score 74 — a cautious pass, reflecting a genuine franchise with concrete barriers but a price that embeds meaningful growth assumptions that a conservative EPV investor accepts only reluctantly.

Key points

EPV ~$98/share at zero-growth (NOPAT ~$1.1B / WACC 8%), well below $195 market price — market is pricing in ~$97/share of growth premium
ROIC of 18% vs. WACC 8% — 10-point spread sustained over multiple years confirms genuine franchise, not a mean-reverting commodity business
Concrete moat sources: cloud-integrated CPAP compliance data creates high switching costs; physician-channel prescription dynamics generate customer captivity; 30+ year installed base with recurring consumable revenue
FCF compounded from $634M (FY2021) to $1,662M (FY2025), margins expanded from 20% to 32% FCF margin — earnings power is real and rising, not manufactured
Asset-light model (capex only $90M on $5.1B revenue) means reproduction cost for tangible assets is low; EPV >> tangible reproduction value confirms franchise value
P/FCF of 17x and P/E of 20x are modest multiples for a franchise-quality business — not bubble territory, but not a deep-value discount either
Minimal leverage (D/E 0.17x), $1.4B cash, current ratio 3.1x — balance sheet provides resilience and optionality

Red flags

Growth premium embedded in price (~$97/share above EPV) requires sustained above-WACC growth inside the moat — acceptable only if franchise barriers are durable, which GLP-1 risk puts in question
GLP-1 structural headwind is a genuine EPV risk, not merely a DCF tail risk — if normalized OSA incidence declines, the earnings base itself (not just growth) could compress over 5-10 years
No earnings call transcript available to assess management's own GLP-1 analysis or FY2027 guidance — key data gap for normalizing earnings power
DCF intrinsic value of $321/share relies heavily on terminal value (80% of EV from TV) — exactly the long-horizon speculation Greenwald distrusts; treat as an upper bound sanity check, not an anchor
RBC downgrade and CEO share sales post-option-exercise are soft negative signals; insider selling at 30% below peak is not alarming but warrants monitoring
MatrixCare divestiture reduces revenue diversification; Noctrix acquisition rationale is unclear — serial M&A can obscure true organic earnings power and complicates normalization

Michael Mauboussin — 🟢 pass · 74/100 · medium confidence

ResMed presents a compelling quality franchise at expectations that appear achievable or conservative. The ROIC/WACC spread is real and widening: ROIC of 17.99% vs. WACC ~7.96% yields a spread of roughly 1000 bps — wide by any standard, and validated by improving FCF margins (19.8% in FY21 → 32.3% in FY25), expanding operating margins (32.75%), and a net margin of 27.2%. These are not random — they are structural. The moat sources are concrete: (1) switching costs are high — CPAP patients are titrated on specific devices, physician workflows are embedded, DME/HME supply chains are reorder-sticky, and the Brightree/SaaS software layer (now partially divested with MatrixCare sale) created additional procedural lock-in; (2) scale economies are real — RMD has ~35-40% global CPAP market share (Philips recall beneficiary), manufacturing scale, and a proprietary cloud-connected device ecosystem (AirSense, myAir platform) with ~15 million active patients generating data network effects that competitors cannot easily replicate; (3) intangibles include a strong regulatory/FDA relationship, 5,400+ patents, and clinical-grade algorithm IP embedded in device firmware. The expectations check is favorable: at $195.27, the market implies roughly 12% FCF growth (the DCF base assumption) to justify the price — exactly the 3-year revenue CAGR. The DCF base case yields $321.64/share, implying 65% upside, with a bear case of $249.45 still 28% above current price. P/FCF of 17x and P/E of 20x for a business compounding FCF at 30%+ margins and ROIC ~18% is not demanding. The price appears to be embedding a meaningful deceleration scenario — possibly pricing in some probability of GLP-1 headwinds. The GLP-1 risk is the central distributional question and deserves serious weight: if GLP-1 drugs meaningfully reduce OSA incidence by treating underlying obesity over a 5-10 year horizon, the installed-base moat erodes and the new patient funnel shrinks. However, the base-rate evidence cuts against catastrophe: (a) OSA is not purely obesity-driven — anatomical/structural causes persist; (b) GLP-1 adherence is low (estimated 50%+ discontinuation by year 2); (c) the existing installed base of 936M+ sufferers globally ensures decades of addressable demand; (d) RMD is pivoting toward digital health and care management to reduce GLP-1 dependency on device growth. The CPAP obsolescence risk (Apnimed etc.) is real but distant — oral therapies face FDA hurdles, reimbursement barriers, and compliance monitoring challenges CPAP already solved. AI/technology is a net positive for RMD: their cloud-connected device ecosystem generates proprietary adherence data that strengthens physician relationships and payor value propositions — AI-enhanced titration algorithms and predictive adherence scoring are competitive differentiators that deepen switching costs rather than commoditize the moat. The primary concerns are: (1) MatrixCare divestiture removes a recurring SaaS revenue stream that provided moat diversification — need to understand reinvestment of proceeds; (2) Noctrix acquisition rationale is unclear from available data — risk of ROIC-dilutive M&A; (3) insider selling by CEO post-exercise is contextually ambiguous but worth noting; (4) the 80% terminal value dependency in the DCF is high and sensitive to terminal growth assumptions. Capital allocation has been disciplined historically (capex/revenue ratio ~1.7%, strong FCF conversion), but the M&A activity needs monitoring. Outcome distribution: bull case (30% prob) — GLP-1 risk overstated, OSA market expands, ROIC stable at 18%+, stock at $350+; base (50% prob) — moderate GLP-1 headwind offset by international growth and software, ROIC ~15-18%, stock $280-320; bear (20% prob) — GLP-1 meaningfully disrupts patient funnel, new entrants gain share, ROIC compresses toward WACC, stock $180-220. Expected value materially above current price. Score 74: strong moat with concrete mechanisms, favorable expectations embedded in price, real but manageable tail risks, with uncertainty around GLP-1 and M&A execution preventing a higher score.

Key points

ROIC of ~18% vs. WACC ~8% = ~1000 bps spread, validated by FCF margin expansion from 19.8% (FY21) to 32.3% (FY25) — not luck, structural
Concrete moat: high switching costs (device/software/physician workflow lock-in), scale economies (~35-40% CPAP global share), 15M+ connected patients generating proprietary data network effects, 5,400+ patents
Price implies ~12% FCF growth — exactly the 3-year CAGR — suggesting market is embedding significant GLP-1 deceleration risk; bear DCF at $249.45 still 28% above current price
GLP-1 risk is real but overstated at current price: OSA has structural/anatomical causes beyond obesity, GLP-1 adherence rates are low (~50% discontinue by year 2), global OSA burden is enormous
AI/technology is a net moat strengthener: AirSense cloud ecosystem and adherence AI deepen physician integration and payor value prop, raising switching costs rather than commoditizing them
P/FCF of 17x and P/E of 20x for 32% FCF margins and 18% ROIC is not demanding — expectations appear conservative relative to historical delivery

Red flags

MatrixCare divestiture removes recurring SaaS revenue moat diversification; need clarity on capital redeployment to avoid ROIC-dilutive reinvestment
Noctrix acquisition strategic rationale unclear from available data — risk of empire-building M&A at suboptimal returns
DCF terminal value is 80% of enterprise value — high sensitivity to terminal growth rate assumption; if OSA market structurally deflates, terminal value collapses disproportionately
No Q4 FY2026 earnings call transcript available — unable to assess management's probabilistic framing of GLP-1 headwind or FY2027 guidance; this is a meaningful information gap
RBC Capital Markets downgrade in mid-July 2026 signals institutional caution; insufficient context to evaluate whether this represents an informed view or is isolated
Insider selling by CEO post-exercise is ambiguous but, combined with stock at 30% below peak, warrants monitoring of management's own conviction assessment

Ray Dalio — 🟢 pass · 72/100 · medium confidence

ResMed passes the Dalio regime-stress test with meaningful caveats. Its core strength is that sleep apnea treatment is non-discretionary healthcare — patients on CPAP therapy need consumables and device replacements regardless of the macro cycle. This gives it unusual cash-flow durability across regimes. In a stagflation scenario (rising inflation, slowing growth), RMD's pricing power (device and mask ASPs historically rising, healthcare inflation typically passes through to payers/patients) and near-zero net debt position it better than most industrials. In a deflationary bust/deleveraging scenario, non-discretionary medical demand holds up better than consumer discretionary or capital-intensive sectors. In a boom scenario, patient volumes expand further and the balance sheet remains self-funding. The primary regime vulnerability is a high-rate/low-growth scenario where healthcare payers tighten reimbursement — a genuine risk but not catastrophic given the clinical necessity of OSA treatment. Balance sheet is fortress-like: D/E of 0.17, current ratio of 3.06, net cash position (cash $1.42B vs. long-term debt $1.08B = net cash ~$340M), FCF of $1.66B vs. capex of only $90M, meaning the business is essentially self-funding and does not depend on capital markets. FCF margin of 32% is remarkable across-cycle resilience. ROIC of 18% signals genuine capital efficiency. Rate sensitivity is LOW — the company has no meaningful floating-rate refinancing exposure on its modest debt load, and its customers (patients, insurers) are not leveraged credit buyers whose demand would collapse in a credit contraction. Revenue is highly recurring (consumable masks, tubes, humidifiers) rather than lumpy capex-dependent one-time device sales. Geographic diversification is real — roughly 45–55% revenue from the Americas, balance from Europe, Asia-Pacific, and Rest of World, providing FX diversification and some insulation from a US-specific downturn. However, this also introduces EM/currency translation risk if the USD strengthens in a flight-to-safety scenario. Inflation pass-through: medical device pricing is partially constrained by payer contracts and Medicare fee schedules, which is a partial red flag — RMD cannot freely pass all input cost inflation. However, gross margins have been expanding (not compressing) in the recent inflationary period, suggesting meaningful pricing power within these constraints. Key macro red flag: the GLP-1 structural demand risk is a genuine long-cycle concern — if obesity rates fall materially over a 5–10 year horizon, the patient funnel for OSA devices shrinks. From a Dalio lens, this is a slow-moving secular headwind, not a cyclical/regime risk, so it does not dominate the regime-robustness score but it does dampen the bull case. Single-regime dependence is NOT a major issue here — unlike a leveraged growth tech name or a housing-sensitive business, RMD's cash flows are anchored in clinical necessity. The DCF base case of $321/share (64% upside) suggests substantial margin of safety even in a bear scenario of $249, implying limited valuation risk of a regime-shift repricing. Correlation to broad equity beta is low (beta 0.76), consistent with defensive health care positioning. AI/disruption: AI could enhance RMD (better adherence monitoring, remote diagnostics, personalized therapy) or threaten it via commoditization of device software. Near-term, AI is likely a tailwind for their connected-device ecosystem; the risk is longer-term if AI-enabled alternatives (e.g., drug-based OSA treatment via GLP-1s) disintermediate the hardware moat. MatrixCare sale simplifies the portfolio and reduces software-revenue complexity, modestly reducing the diversification story but improving capital allocation focus. Score docked from potential 80+ to 72 due to: partial inflation pass-through constraints from payer contracts; GLP-1 structural demand risk as a long-cycle headwind; insider selling signal and RBC downgrade adding uncertainty; and the fact that this is a relatively concentrated US-listed health care name that adds modest diversification to a typical equity book.

Key points

Net cash balance sheet (~$340M net cash) with D/E of 0.17 and current ratio of 3.06 — virtually no debt-cycle or refinancing risk
FCF of $1.66B on $5.15B revenue (32% FCF margin) with capex of only $90M — self-funding across all plausible macro regimes
Non-discretionary clinical demand (sleep apnea treatment is medically necessary) provides regime robustness in stagflation and deflationary bust scenarios
Revenue 45-55% Americas / balance international — genuine geographic diversification reduces home-currency and single-economy concentration risk
Beta 0.76 and healthcare sector positioning provide low correlation to typical equity book, consistent with Dalio's 'Holy Grail' diversification principle
DCF bear case of $249/share implies 27% upside even at stressed assumptions — meaningful margin of safety against regime-shift repricing
Revenue CAGR of 12.9% over 3 years with expanding FCF margins (from 20% in 2021 to 32% in 2025) demonstrates through-cycle compounding
Pricing power evidenced by expanding gross/net margins through 2021-2025 inflationary period despite partial payer-contract constraints

Red flags

GLP-1 weight-loss drugs represent a genuine long-cycle structural headwind to OSA patient funnel — not quantified but directionally negative over 5-10 year horizon
Medicare/insurance payer contract constraints limit full inflation pass-through — partially limits pricing power in sustained high-inflation regime
MatrixCare divestiture reduces software/recurring-revenue diversification, concentrating cash flows more in hardware/consumables subject to device-cycle risk
CEO insider selling post-option-exercise and RBC downgrade introduce near-term uncertainty about management conviction and institutional sentiment
Residential Care Software segment performance and strategic direction post-MatrixCare sale not fully transparent in available filings
80% of DCF value is in terminal value — high sensitivity to terminal growth and WACC assumptions; a sustained higher-for-longer rate regime would pressure terminal value meaningfully
No Q4 FY2026 earnings call transcript available — management's own framing of GLP-1 risk and FY2027 guidance cannot be directly assessed

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

ResMed operates in medical device hardware (CPAP/BiPAP machines, masks, accessories) plus a software layer (Brightree, MatrixCare — though MatrixCare is being divested). The core disruption question is: can AI/automation remove the need for RMD's physical devices, data platform, or care management software? The answer is nuanced and largely favorable for RMD over a 3-10 year horizon, but with one genuine structural risk that must be tracked.

What job does RMD do? It manufactures and distributes FDA-regulated respiratory therapy devices, sells consumable masks/accessories creating recurring revenue, and runs a cloud-connected device ecosystem (AirSense/myAir platform) that generates clinical compliance data for payers and physicians. The physical hardware + regulatory clearance + proprietary compliance data loop is the core moat.

Obsolescence test — low for hardware, moderate for software: No AI model can replace the physical act of delivering positive airway pressure to a sleeping patient. The therapy is physical, not informational. This is a critical distinction from digital intermediaries: AI cannot disintermediate the device itself. However, the software/analytics layer (diagnosis routing, adherence coaching, care coordination) is more exposed — AI agents could theoretically handle remote patient monitoring, titration recommendations, and compliance nudging that RMD currently monetizes through its SaaS offerings.

The GLP-1 structural risk is the bigger disruption than AI: The bear narrative correctly identifies that GLP-1 drugs reducing obesity prevalence is a more proximate demand-side threat than AI commoditizing RMD's moat. This is not an AI disruption but a medical innovation disruption. However, this lens focuses on AI specifically.

AI as tailwind — strong case: RMed's AirSense 11 and myAir platform already embed ML algorithms for auto-titration, leak detection, and adherence scoring. The proprietary dataset of billions of patient-nights of sleep therapy data is a genuine compound moat — frontier models trained on this data could improve diagnostic accuracy and therapy optimization in ways that raise switching costs and deepen payer/provider integration. This is the opposite of commoditization: RMD owns the data flywheel that AI makes more valuable.

AI as threat — limited but real in software: The MatrixCare divestiture actually reduces RMD's exposure to the more commoditizable healthcare IT/workflow software space. What remains (AirView, myAir) is tightly coupled to device compliance data that third parties cannot replicate without the device installed base. A hyperscaler (Google Health, Amazon HealthLake) could theoretically offer competing analytics, but lacks the device-generated first-party data.

Management honesty: No direct transcript available, but the AirSense platform investments and the Noctrix acquisition (neuromuscular electrical stimulation for sleep apnea — an alternative therapy) suggest some awareness of the need to expand beyond pure CPAP. This is a positive signal. The MatrixCare sale reduces distraction.

Falsifiable call: AI displacement confirmed if: third-party AI platforms begin capturing adherence/titration analytics revenue, payers bypass RMD data streams, or AI-enabled diagnosis routes patients to alternative (non-CPAP) therapies faster than RMD can capture that TAM. AI tailwind confirmed if: AirView/myAir take-rates rise, compliance data becomes a payer contracting advantage, and Noctrix-type acquisitions show RMD capturing adjacent AI-enhanced therapy modalities.

Key points

Physical device manufacturing with FDA regulatory clearance creates a durable barrier AI cannot replicate — no disintermediation mechanism exists for the therapy itself
Proprietary dataset of billions of patient-nights of sleep data is a compounding AI moat — harder to replicate as RMD's installed base grows, not easier
AirSense platform already embeds ML for auto-titration and adherence — RMD is becoming the AI layer in its own ecosystem rather than being displaced by one
MatrixCare divestiture reduces exposure to commoditizable healthcare IT software where AI-native entrants are most threatening
Noctrix acquisition signals awareness that non-CPAP sleep apnea therapies (neuromuscular stimulation) may capture GLP-1-resistant patients — optionality on adjacent modalities
Revenue model (device + recurring consumables + SaaS compliance data) is multi-layered; the recurring consumables stream (masks, tubing) is essentially immune to AI disruption
Beta of 0.75 and 32% FCF margin suggest market already prices in some structural risk, creating asymmetry if AI moat thesis proves out

Red flags

Software/analytics layer (AirView, myAir) is theoretically replicable by well-capitalized health IT platforms (Google Health, Epic, Amazon) that could bundle remote patient monitoring — RMD must maintain data exclusivity
GLP-1 drugs reducing obesity prevalence is a medical innovation disruption to the demand funnel that is more near-term and quantifiable than AI risk — could shrink the patient pool needing devices regardless of RMD's technology position
No Q4 FY2026 earnings call transcript available — unable to assess whether management explicitly addresses AI strategy for data moat vs. treating it purely as a product feature
Noctrix acquisition rationale unclear to the market — if RMD is pivoting to neuromodulation it may face unfamiliar AI-competitive dynamics in that adjacent space
Insider selling by CEO post-option exercise, combined with RBC downgrade, suggests institutional caution about near-term catalysts that could delay realization of the AI data-moat thesis

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 72/100 · medium confidence

ResMed passes the forensic short-seller screen with notable strength on the core earnings-quality test: net income of $1.40B is actually BELOW operating cash flow of $1.75B and free cash flow of $1.66B, which is the opposite of the Chanos red flag. FCF has accelerated dramatically from $216M in FY2022 to $1.66B in FY2025, with FCF margins expanding from 6% to 32% — a pattern consistent with genuine earnings quality improvement, not manufactured earnings. Operating margin of 32.8% and FCF margin of 32.3% are tightly aligned, suggesting minimal aggressive capitalization of costs. The balance sheet is fortress-like: current ratio of 3.06, debt-to-equity of only 0.17, $1.42B cash vs. $1.08B long-term debt (net cash position of ~$338M), and no visible debt wall or refinancing dependence. These are structurally unshortable characteristics from a Chanos framework. However, several watchpoints exist that prevent a clean dismissal of any short case: (1) The 52-week high discrepancy in the fact base is suspicious — one field shows $209.63 as the high while another shows $293.81, suggesting the stock has actually fallen ~34% from peak, not 6.85%; the narrative confirms 'down 30% from peak.' This matters for sentiment and may indicate a broken momentum story. (2) The MatrixCare divestiture reduces recurring software revenue, and the Noctrix acquisition rationale is unclear — serial M&A with unclear strategic logic is a Chanos watch item. (3) Insider selling post-option exercise by the CEO is noted, though context (tax optimization) weakens this signal. (4) The GLP-1 structural demand headwind is a legitimate TAM-compression story — if obesity drugs reduce OSA incidence over a 5-10 year horizon, the installed base replacement cycle and new patient funnel both compress. This is not an accounting fraud risk but is a unit-economics deterioration risk. (5) The DCF valuation assumes 12% FCF growth perpetuated from an already-peak FCF margin base of 32% — if GLP-1 headwinds materialize, this growth rate is optimistic, but even the bear DCF ($249) is above current price, limiting short upside. (6) RBC downgrade and Russell Growth Index removal are mild negative catalysts but not thesis-makers. The kill question for a short thesis would require: (a) evidence that GLP-1 drugs are materially reducing diagnosed OSA incidence in clinical data, AND (b) management guidance cutting FY2027 revenue growth below 5%, AND (c) FCF margin compression below 20% as CPAP volumes plateau. None of these are currently present. The bear case disproof is simple: FCO consistently exceeds net income, balance sheet has net cash, and the business generates real cash. This is not a short.

Key points

FCF of $1.66B exceeds net income of $1.40B — earnings quality is HIGH; CFO/NI ratio >1.25x is the OPPOSITE of the Chanos short screen
FCF margin expanded from 6% in FY2022 to 32.3% in FY2025 — genuine improvement, not aggressive accrual manipulation
Balance sheet shows net cash (~$338M): $1.42B cash vs. $1.08B long-term debt; debt-to-equity 0.17; no refinancing dependence or debt wall
Operating margin (32.8%) and FCF margin (32.3%) are tightly aligned, suggesting minimal capitalized cost manipulation
Current ratio of 3.06 and low capex ($90M on $5.1B revenue = 1.7% intensity) indicate low capital intensity and no balance-sheet stress
P/E of 20.2x and P/FCF of 17.1x are modest multiples for a business with 32% FCF margins — short upside is structurally limited
DCF bear case of $249 remains above current price of $195, meaning even the pessimistic scenario implies upside, not a short opportunity

Red flags

52-week high data inconsistency: one field shows $209.63, another $293.81 — stock appears down ~34% from peak, suggesting broken momentum that warrants monitoring
GLP-1 structural demand headwind is a credible long-term TAM compression risk — if obesity drugs reduce OSA incidence, new patient funnel shrinks over 5-10 years; not quantified yet but directionally negative
MatrixCare divestiture reduces recurring software revenue mix; Noctrix acquisition rationale unclear — serial M&A with ambiguous strategy is a governance watch item
CEO sold ~5,000 shares post-option exercise (June 2026) and RBC Capital Markets issued a downgrade in mid-July — modest but directionally negative insider/analyst signals
DCF assumes 12% perpetual FCF growth from an already-peak 32% FCF margin base — if GLP-1 headwinds compress volumes, this assumption is vulnerable
No Q4 FY2026 earnings call transcript available — inability to assess management's GLP-1 framing or FY2027 guidance is an information gap

Peter Lynch — 🟡 watch · 58/100 · medium confidence

ResMed is a classic stalwart — a dominant medical device company with a defensible niche (CPAP/sleep apnea) growing revenue at ~13% CAGR and generating exceptional free cash flow. The business is utterly explainable: they make machines that help people breathe at night, and roughly 1 billion people worldwide have sleep apnea. That's the kind of story I love. But the PEG is the problem. Reported PEG is 1.57 — well above my 1.0 threshold for a stalwart. The P/E of ~20x is actually modest in isolation, but the earnings growth rate to justify it needs to be 20%+, and RMD is more of a 12-13% grower, not a fast grower. FCF is stellar ($1.66B, 32% FCF margin) and the balance sheet is fortress-like: debt/equity of 0.17, current ratio of 3.06, net cash position of ~$338M. ROE of 22% and ROIC of 18% confirm capital efficiency. The trouble is categorization: this is a stalwart, and for stalwarts I'd want to buy at 30-50% below fair value and sell after a 30-50% gain — the DCF says 64% upside at $321/share, which is interesting. However, the GLP-1 structural risk is genuinely novel and credible: if obesity drugs reduce sleep apnea incidence over a 5-10 year horizon, the earnings growth story gets complicated. That's not speculation — it's a biological mechanism I can understand. The MatrixCare sale (divesting software) and Noctrix acquisition (mixed rationale) smell of diworsification risk, though scale is unclear. Insider selling post-exercise is a mild negative. The stock is down 30%+ from peak, which creates potential value, but for a Lynch stalwart I want earnings growth to be accelerating, not facing a credible demand headwind. Net-net: strong business, clean balance sheet, reasonable multiple — but PEG above 1, structural demand uncertainty from GLP-1, and M&A complexity push this into 'watch' territory. Not a avoid, but not a confident buy until the August 6 earnings call clarifies GLP-1 impact on demand and MatrixCare exit proceeds are deployed intelligently.

Key points

Category: Stalwart — ~13% revenue CAGR, dominant in sleep apnea devices, not a fast grower. Judging on stalwart criteria.
PEG of 1.57 exceeds my 1.0 threshold; P/E of 20x is not cheap enough for a ~13% grower without a catalyst to re-accelerate growth.
Exceptional FCF: $1.66B in FY2025, 32% FCF margin, up from 20% in 2021 — genuine operational excellence and not accounting trickery.
Balance sheet is solid: D/E of 0.17, current ratio of 3.06, net cash of ~$338M — funds growth internally, no leverage risk.
Business is understandable: CPAP machines + mask resupply recurring revenue + software services; billion-person TAM is the growth runway.
DCF intrinsic value of $321/share implies ~64% upside — this is the most compelling Lynch-style argument for the stock at current price.
Revenue CAGR of 12.9% and net income growth from $475M (2021) to $1.4B (2025) shows a real, sustained earnings-growth story.
AI/tech disruption: AI actually benefits RMD — their AirSense connected devices and cloud platform (myAir) generate data that strengthens the physician relationship and creates switching costs. AI-driven adherence coaching could increase CPAP compliance and expand the addressable market. Not a disruption victim; potentially a beneficiary.

Red flags

GLP-1 structural headwind: Weight-loss drugs reducing obesity could shrink the future sleep apnea patient funnel over 5-10 years — a credible, quantifiable risk that management has not yet fully addressed publicly.
PEG of 1.57 is above Lynch's comfort zone for a stalwart; paying 20x earnings for ~13% growth leaves little margin for error if growth decelerates.
MatrixCare divestiture + Noctrix acquisition raises diworsification concern — management appears to be reshaping the business at a time when clarity on core demand is most needed.
No recent earnings call transcript available — cannot assess management's own read on GLP-1 impact, FY2027 guidance, or capital allocation priorities.
RBC Capital Markets downgrade in July 2026 adds to institutional caution; unclear if broader analyst community is pivoting bearish.
CEO insider selling (~5,000 shares post-exercise) is a minor negative signal, though context (tax diversification) limits its weight.

Seth Klarman — 🟡 watch · 55/100 · medium confidence

ResMed presents an interesting value case but does not cleanly meet my margin-of-safety bar. The DCF intrinsic value of $321.64/share implies ~65% upside from $195.27, which is superficially attractive. However, my discipline requires me to apply a conservative, multi-method appraisal and stress-test the downside first — and the DCF is not conservative. It assumes 12% FCF growth (the revenue CAGR) compounded for 5 years with 2.5% terminal growth, which bakes in substantial optimism given the structural uncertainties around GLP-1 drug penetration and CPAP demand trajectory. If I haircut those assumptions meaningfully — say 6-7% growth and a 2% terminal rate — intrinsic value compresses materially. On a normalized FCF yield basis: $1.66B FCF on a $28.3B market cap = ~5.9% yield, which is reasonable but not a screaming discount for a business facing a credible demand headwind. The bear-case DCF of $249.45 still implies upside, but that bear case may itself be too optimistic if GLP-1 drugs genuinely compress the patient funnel over a 10-year horizon — a risk that is difficult to quantify today. Balance sheet is genuinely strong: current ratio of 3.06, only $1.08B long-term debt vs. $6.32B equity, $1.42B cash, and $1.66B annual FCF. Debt-to-equity of 0.17 means the balance sheet passes my stress test — there is no leverage fragility. The business generates real, recurring cash flows with high FCF margins (32%), growing from 20% in FY2021 to 32% in FY2025, and operating margins of 32.7%. This is a high-quality, durable franchise, not a distressed or complex situation. The MatrixCare sale is a potential catalyst (capital redeployment, focus simplification) but the strategic narrative is muddied by the concurrent Noctrix acquisition. Insider selling post-exercise is not alarming in isolation, but the RBC downgrade and the stock sitting 34% below its 52-week high (from other data: 52w high of $293.81) suggests the market is pricing in a structural narrative shift, not just temporary multiple compression. The P/E of 20x and P/FCF of 17x are modest but not cheap enough for my bar — I need a meaningful margin of safety after accounting for the GLP-1 wild card, which I cannot yet size. AI and technology are net neutral-to-positive for RMD in the near term: CPAP devices increasingly embed connectivity and AI-driven compliance monitoring (AirSense 11 platform), which deepens the installed-base moat and creates switching costs. However, if AI accelerates drug-based sleep apnea treatment discovery or improves diagnostic pathways that route patients to pharmacological rather than device-based solutions, the moat erodes over 5-10 years. This is a watch, not a pass: the balance sheet safety is real, FCF generation is impressive, and the discount to DCF is meaningful. But the terminal value dependency (80% of DCF value), the unquantified GLP-1 structural risk, and the absence of a hard catalyst make this a situation I would monitor rather than commit capital to today. I would revisit aggressively at prices below $170 or if the Q4 FY2026 earnings call provides management's quantified assessment of GLP-1 impact on patient volumes.

Key points

Strong balance sheet: $1.42B cash, only $1.08B LTD, D/E of 0.17, current ratio 3.1 — no leverage fragility
Record FCF of $1.66B (32% FCF margin) provides real cash earnings foundation; P/FCF of 17x is modest
DCF implies 65% upside ($321.64 intrinsic vs $195.27 price), bear case still shows upside at $249.45
Stock is ~34% below 52-week high of $293.81 — significant price dislocation may signal opportunity or structural re-rating
Revenue CAGR of 12.9% and improving margins from FY2021-2025 demonstrate compounding quality
MatrixCare asset sale could be a value-unlocking catalyst if proceeds are deployed intelligently
AI-embedded CPAP devices (AirSense platform) deepen switching costs and installed-base moat

Red flags

DCF is 80.1% terminal value — intrinsic value is highly sensitive to growth and terminal assumptions; conservative stress test compresses value significantly
GLP-1 structural risk (obesity drug penetration reducing OSA incidence) is unquantified and could impair the patient funnel over a 10-year horizon — this is my primary concern
12% growth assumption in DCF may be optimistic; normalizing to 6-7% reduces intrinsic value well below current price
No hard catalyst to close the value gap — MatrixCare sale rationale and Noctrix strategic fit both unclear
RBC Capital Markets downgrade in July 2026 and stock weakness suggest institutional consensus may be shifting bearishly on demand outlook
P/FCF of 17x and P/E of 20x are fair-to-modest multiples, not genuinely cheap by my bar — insufficient margin of safety given unknowns
Insider selling post-exercise (CEO, June 2026) and stock 30% below peak reduce my confidence that insiders see a near-term recovery catalyst

Howard Marks — 🟡 watch · 55/100 · medium confidence

ResMed sits in an interesting middle ground through the Howard Marks lens. The stock has declined ~30% from its peak ($293.81 52-week high shown in fundamentals vs. current $195.27), which on the surface looks like the pendulum has swung toward fear — exactly the kind of price dislocation I find interesting. The DCF at WACC 7.96% spits out a base intrinsic value of $321.64 with 64.7% upside, and even the bear case ($249.45) implies meaningful discount to current price. That is real margin of safety in the abstract. However, before declaring this a contrarian gift, I must interrogate what is actually priced in and whether the bear case assumptions are conservative enough.

On price vs. value: The FCF story is genuinely impressive — $1.66B FCF on $5.15B revenue is a 32.3% FCF margin, P/FCF of 17x, and the company carries net cash of ~$338M with D/E of just 0.17. The balance sheet is fortress-like: current ratio 3.06, $1.42B cash, only $1.08B long-term debt, and operating cash flow of $1.75B far exceeds any conceivable debt service requirement. This is not a fragile capital structure. ROIC of 18% and ROE of 22% confirm genuine competitive returns. These are real numbers from the filings, not narrative.

On second-level thinking and what is priced in: Here is where I must be more cautious than the DCF suggests. The consensus bull case is well-understood — dominant CPAP franchise, recurring supply revenue, strong FCF conversion, relatively cheap P/E of ~20x vs. market. The bear case embedded in the price is primarily the GLP-1 structural headwind: if obesity drugs reduce sleep apnea prevalence materially, the patient funnel shrinks and the installed base does not get replaced at historical rates. This is not paranoia — it is a plausible structural demand inflection that the market is already partially pricing in (stock down 30% from peak). But has it been fully discounted? The DCF uses 12% FCF growth and a 2.5% terminal rate — if GLP-1 adoption genuinely crimps new patient volumes 5-10 years out, the terminal value (which represents 80% of the DCF's intrinsic value) could be substantially impaired. That 80% terminal value dependence is a meaningful vulnerability in the valuation math.

On cycle and sentiment: Sentiment has shifted from euphoric (2021-2022 post-COVID CPAP tailwind) to cautious. RBC downgrade, Russell Growth removal, insider selling (modest but noted), MatrixCare divestiture creating strategic uncertainty — these are the fingerprints of institutional discomfort. That is contrarian-favorable. However, this is not a distressed, forced-sale situation. The stock is off peak but still trades at 5.5x sales and 20x P/E — these are not bombed-out multiples. The bar is not as low as the 30% drawdown implies.

On AI and technological disruption: AI actually cuts mixed here. On the positive side, ResMed's AirSense connected device platform and cloud data infrastructure (Brightree, MatrixCare — though MatrixCare is being sold) are AI-enablers; AI-driven adherence monitoring and titration optimization could deepen the moat and reduce churn. On the negative side, AI accelerates the GLP-1 risk indirectly by improving drug efficacy monitoring and personalization, and could enable competitor devices (Apnimed pharmacological approach, implantable neurostimulators) to displace CPAP more rapidly if clinical outcomes data are processed faster. Net: modest AI tailwind near-term, uncertain medium-term.

On asymmetry: The downside is genuinely limited by the balance sheet — this company cannot go bankrupt, and the FCF generation provides continuous optionality. The upside via DCF is large. However, the permanent-loss scenario is not zero — it is a slow-motion demand impairment where multiples compress and growth disappoints for years. That is not catastrophic but it is real. I need a wider margin of safety given this structural uncertainty than the current ~65% DCF upside provides when 80% of that value rests in a terminal growth assumption that may not materialize if GLP-1s reshape the OSA population.

Key points

Balance sheet is fortress-grade: D/E 0.17, net cash positive ~$338M, current ratio 3.06, $1.42B cash — zero capital structure risk, strong ability to survive downside scenarios
FCF generation is exceptional: $1.66B at 32.3% margin, P/FCF 17x — this is real cash, not accounting earnings, supporting the margin of safety
30% drawdown from $293.81 peak has moved sentiment from euphoric to cautious — contrarian-favorable direction, though not yet bombed-out or forced-selling dynamics
DCF shows $321.64 base intrinsic value (65% upside) and even bear case $249.45 implies ~28% upside — meaningful discount exists
GLP-1 structural demand risk is emergent but NOT yet fully quantified — this is the key variant view question; the street has partially but perhaps not fully repriced this risk
Terminal value represents ~80% of DCF intrinsic value — this extreme back-loading makes the 'intrinsic value' highly sensitive to long-run growth assumptions, which are exactly what GLP-1s threaten
MatrixCare divestiture removes recurring SaaS revenue stream; strategic coherence of remaining portfolio (Noctrix acquisition rationale unclear) adds execution uncertainty

Red flags

Terminal value dependence (80% of DCF) means the valuation is highly leveraged to a 2.5% perpetual growth assumption — if GLP-1s inflect OSA patient volumes downward, this terminal value is materially impaired and the current 'discount' may be illusory
GLP-1 structural demand headwind is a genuine second-order risk that the obvious bull case (strong FCF, cheap P/E) does not adequately address — the crowd sees the cheap P/E but may be underweighting the secular demand question
P/E of 20x and P/Sales of 5.5x are not bombed-out multiples — the price does not yet fully embed a pessimistic outcome; margin of safety is present but not extreme
Insider selling post-option exercise by CEO (modest scale) and RBC downgrade suggest the easy money on the rebound may already be gone; no capitulation signal yet
Revenue CAGR of 12.9% used in DCF growth assumption may prove optimistic if new CPAP patient starts slow — this is the single biggest model sensitivity

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

RMD presents a mixed Druckenmiller-style setup. The fundamentals are genuinely strong — record FCF of $1.66B, 32% FCF margins, 12.9% revenue CAGR, and accelerating profitability (net margin expanding from ~14.8% in 2021 to 27.2% in 2025). The balance sheet is clean: D/E of 0.17, current ratio of 3.06, net cash positive. These are the kind of clean financials that let you run a directional thesis. However, the critical Druckenmiller filter is WHERE THINGS ARE HEADING, and here the picture clouds significantly. The tape is unambiguously broken — RMD is down ~30% from its 52-week high of $293.81, sitting at $195.27, at or near its 52-week low. Price is not confirming any bullish thesis; it is in distribution. The second derivative concern is real: while FCF grew impressively 2024-2025, the GLP-1 structural headwind introduces genuine uncertainty about the FORWARD earnings trajectory and rate of change of patient funnel growth. RBC downgraded in July; the analyst community is not providing positive estimate revision momentum. On the macro/liquidity angle, the Fed posture is ambiguous — no clear easing cycle underway that would provide a strong liquidity tailwind. The MatrixCare sale removes a software revenue stream while the Noctrix acquisition rationale is unclear to the market, adding M&A noise rather than a clean, readable earnings trajectory. The 'why now' catalyst — Q4 FY2026 earnings on August 6 — is a binary event, not a sustained directional driver I can ride with conviction. The GLP-1 headwind is not yet quantified by management; it is an unresolved, potentially material structural risk that makes sizing up dangerous. For Druckenmiller-style positioning, I need the tape confirming the thesis, estimate revisions moving up, and a macro/liquidity tailwind. Currently one of three is at best neutral and two are working against me. The DCF suggests ~65% upside to $321/share intrinsic value — attractive if the thesis inflects — but mean-reverting to intrinsic value is a value investor's framework, not mine. I want the stock already moving in my direction before I size up.

Key points

FCF accelerating strongly: $634M (2021) to $1.66B (2025), FCF margin expansion from 19.8% to 32.3% — clean financials, readable trajectory
Revenue CAGR of 12.9% over 3 years with operating margin at 32.75% — operational engine is elite
Balance sheet fortress: D/E 0.17, net cash positive, current ratio 3.06 — no balance sheet risk to thesis
DCF intrinsic value $321/share implies 65% upside, bear case $249 still +28% — asymmetry exists IF thesis is intact
Q4 FY2026 earnings (Aug 6) is an imminent catalyst that could re-rate estimates upward or downward — binary event
ROIC of 18% signals durable competitive moat in CPAP/sleep-breathing devices

Red flags

TAPE IS BROKEN: Stock at 52-week low, down ~30% from $293.81 peak — price disagreeing with bullish thesis is a primary Druckenmiller disqualifier
GLP-1 structural headwind is an unquantified forward earnings risk — the second derivative of patient funnel growth may be inflecting negative, the exact wrong direction
RBC Capital Markets downgrade July 2026 — analyst estimate revisions moving in wrong direction, no positive revision momentum
CEO insider selling post-option exercise June 2026 — weak internal conviction signal at elevated levels
MatrixCare divestiture removes software/cloud recurring revenue; Noctrix acquisition rationale opaque — M&A noise obscures clean earnings trajectory
No clear Fed/liquidity tailwind identifiable; macro regime not providing easing cycle support for the thesis
Russell Growth Index removal triggered technical selling pressure — institutional flow headwinds, not tailwinds
No earnings call transcript available; management's own framing of GLP-1 impact completely unknown — cannot define invalidation point clearly

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

ResMed passes several Graham quality tests but fails the core valuation tests that define a margin-of-safety purchase. Starting with what Graham would like: the balance sheet is genuinely strong — current ratio of 3.06 (well above the 2.0 threshold), current assets of $3.82B against total liabilities of only $2.18B (current assets exceed total liabilities, satisfying that defensive test), and long-term debt of only $1.08B against net working capital of roughly $2.57B ($3.82B minus $1.25B current liabilities), so LTD does not exceed working capital. Earnings are positive, consistent, and growing — net income has risen from $474M (2021) to $1.40B (2025), never negative across the visible history. Operating margins at 32.75% and FCF margins at 32.3% are exceptional for an industrial/healthcare equipment company. ROIC of 17.99% and ROE of 22.16% confirm genuine franchise economics. The company pays a dividend (referenced as attractive in the narrative, though the precise yield is not given in the fact base — a data gap). However, the valuation is where Graham would firmly pump the brakes. P/E of 20.22x exceeds his defensive ceiling of 15x. P/B of 4.48x is elevated. The P/E x P/B product is 20.22 x 4.48 = 90.6, vastly above his combined ceiling of 22.5 — this alone disqualifies the stock as a defensive Graham purchase. There is no possibility of a net-net here: net current assets (current assets minus ALL liabilities) equal $3.82B minus $2.18B = $1.64B, while market cap is $28.3B — price is roughly 17x net current asset value. The DCF intrinsic value of $321.64 suggests 65% upside from $195.27, which is appealing, but Graham was deeply skeptical of DCF-derived values because they depend on growth assumptions extending years into the future; the terminal value comprises 80.1% of enterprise value in this model, a red flag for a conservatively-minded analyst. At 12% assumed FCF growth, the model prices in continued compounding that may not materialize if GLP-1 drugs reduce the OSA patient funnel. Earnings yield of 6.02% (1/P/E) is modestly above current high-grade bond yields, providing some income cushion, but not the wide gap Graham demanded. Price-to-sales of 5.5x is high for a value purchase. The stock is trading near its 52-week low ($195.27 = the low), which is the kind of Mr. Market pessimism Graham appreciated, and it is down roughly 30% from its all-time peak — this is the most compelling Graham-style angle. But cheap relative to a prior high is not the same as cheap relative to demonstrated asset value or normalized earnings. On AI/disruption: the GLP-1 structural risk is real and could impair the earnings trajectory Graham would use to set intrinsic value; AI-driven diagnostics could also commoditize the sleep-monitoring moat over a decade. Neither accelerates the Graham case. On balance, RMD is a high-quality business whose price has come down but not nearly enough to provide Graham's preferred one-third margin of safety against conservatively measured (balance-sheet or earnings-based) intrinsic value. It sits in watch territory — worth monitoring if price declines further toward 12-13x earnings (roughly $145-$160) where the P/E x P/B product would approach acceptable territory.

Key points

Current ratio 3.06, current assets ($3.82B) exceed total liabilities ($2.18B) — balance sheet passes Graham's defensive tests
Long-term debt ($1.08B) is well below net working capital (~$2.57B) — no balance-sheet leverage concern
Earnings consistently positive and growing: net income $474M (2021) to $1.40B (2025), never a loss year in available history
FCF of $1.66B and FCF margin of 32.3% demonstrate genuine cash generation, not accounting fiction
Stock near 52-week low, down ~30% from peak — Mr. Market is pessimistic, which Graham would view as potentially constructive context
DCF intrinsic value of $321.64 implies 65% upside, but 80% of EV is terminal value — dependent on growth assumptions Graham would distrust

Red flags

P/E of 20.22x exceeds Graham's defensive ceiling of 15x — fails primary earnings multiple test
P/E x P/B = 20.22 x 4.48 = 90.6, far above Graham's combined ceiling of 22.5 — fails combined multiple test
Price is ~17x net current asset value ($1.64B) — no possibility of a net-net or near-net-net purchase
Price-to-sales of 5.5x is elevated; Graham preferred modest P/S as a check on growth-story pricing
Terminal value is 80.1% of DCF enterprise value — intrinsic value estimate rests almost entirely on speculative future growth, not demonstrated asset base
GLP-1 drugs could structurally reduce the OSA patient funnel, impairing the earnings trajectory underpinning any value case
MatrixCare divestiture and Noctrix acquisition add M&A noise; unclear capital allocation discipline at current valuations
Dividend yield data missing from fact base — cannot fully verify dividend record reliability, a key Graham quality criterion

Walter Schloss — 🔴 avoid · 22/100 · high confidence

ResMed is a high-quality, asset-light medical device and software business that fails nearly every criterion in the Schloss deep-value framework. The stock trades at 4.48x book value and 5.5x sales — the polar opposite of the near-or-below tangible book bargains Schloss sought. Goodwill and intangibles are substantial relative to the balance sheet (total assets $8.5B vs. stockholders equity $6.3B, with meaningful intangible/software goodwill baked in from acquisitions like MatrixCare). Tangible book is likely a fraction of the stated book value, pushing price-to-tangible-book materially higher than 4.48x. The investment thesis rests entirely on earnings growth, FCF compounding, and a durable market position in sleep apnea — all intangible narrative drivers, not hard assets. Long-term debt of $1.08B is modest in isolation (D/E 0.17), which is one positive, and the current ratio of 3.06 is healthy, but these strengths are overshadowed by the rich multiple to assets. The stock is 6.85% below its 52-week high — not a beaten-down, out-of-favor statistical bargain sitting near multi-year lows. The 52-week low was $180.27; while the stock is down ~30% from its all-time vicinity, it is far from a distressed asset price. Insider selling is flagged (CEO sold shares post-option exercise, counsel surrendered shares). No evidence of meaningful insider ownership accumulation or buying. The business is genuinely excellent on quality metrics — 32% FCF margins, 27% net margins, ROIC 18% — but Schloss explicitly avoided high-quality compounders trading at premiums; he wanted ugly, cheap, and asset-backed. The GLP-1 structural headwind and MatrixCare divestiture add complexity and uncertainty that Schloss would avoid. The DCF suggests ~65% upside to intrinsic value, but that is a growth-dependent, forecast-driven figure — precisely the kind of valuation anchor Schloss distrusted. There is no margin of safety in the hard assets.

Key points

Price-to-book of 4.48x is far above Schloss's preferred near-or-below-book entry point; price-to-tangible-book likely 6-8x or higher given acquisition goodwill
Stock near 52-week high (~6.85% below), not at a multi-year low or in the statistical bargain territory Schloss required
Balance sheet is conservatively leveraged (D/E 0.17, current ratio 3.06) — the one meaningful positive by Schloss standards
Entire thesis is predicated on earnings/FCF growth and brand moat, not on hard tangible assets providing a floor
Insider selling flagged (CEO post-exercise, counsel RSU withholding); no evidence of meaningful insider accumulation
Business complexity increasing: MatrixCare divestiture, Noctrix acquisition, GLP-1 headwind — Schloss preferred simplicity readable from filings

Red flags

P/B of 4.48x with significant goodwill/intangibles means tangible book value provides no margin of safety whatsoever
Trading near 52-week high, not a beaten-down statistical bargain — opposite of Schloss entry criterion
Thesis depends on growth narrative and FCF compounding, not verifiable hard assets on the balance sheet
CEO and insider selling in recent months; no evidence of insider buying or meaningful ownership stake buildup
Acquisition-heavy history (MatrixCare, Noctrix) adds goodwill and complexity Schloss systematically avoided
GLP-1 structural risk introduces long-term demand uncertainty that cannot be resolved by inspecting the balance sheet

Fact base appendix

Price

last_close: 195.27
as_of: 2026-07-27
high_52w: 209.63
low_52w: 195.27
return_1d_pct: -1.87
return_52w_pct: -2.51
pct_below_52w_high: -6.85

Fundamentals

last_price: 195.27
market_cap: 28325163161
fifty_two_week_high: 293.81
fifty_two_week_low: 180.265
beta: 0.7551995
currency: USD
exchange: NEW YORK STOCK EXCHANGE, INC.
sector: Health Care
industry: Health Care
price_source: finnhub
bars: 1
entity: ResMed Inc.
fiscal_year: 2025
revenue: 5146327000
revenue_period: 2025-06-30
net_income: 1400723000
net_income_period: 2025-06-30
operating_income: 1685363000
operating_income_period: 2025-06-30
operating_cash_flow: 1751588000
operating_cash_flow_period: 2025-06-30
capex: 89865000
capex_period: 2025-06-30
total_assets: 8503370000
total_assets_period: 2025-12-31
total_liabilities: 2182491000
total_liabilities_period: 2025-12-31
current_assets: 3818801000
current_assets_period: 2025-12-31
current_liabilities: 1248114000
current_liabilities_period: 2025-12-31
stockholders_equity: 6320879000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 1417069000
cash_and_equivalents_period: 2025-12-31
long_term_debt: 1078611000
long_term_debt_period: 2017-06-30
shares_outstanding: 146414839
operating_margin: 0.3275
net_margin: 0.2722
roe: 0.2216
debt_to_equity: 0.1706
current_ratio: 3.0597
roic: 0.1799
free_cash_flow: 1661723000
fcf_margin: 0.3229
pe_ratio: 20.22
price_to_fcf: 17.05
price_to_sales: 5.5
revenue_cagr: 0.1288
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 4.48
earnings_yield: 0.0602
peg: 1.57

Filings reviewed

8-K (2026-07-07) https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/d88958d8k.htm
10-Q (2026-05-01) https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/rmd-20260331.htm
8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm
8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197192/d146862d8k.htm
10-Q (2026-01-30) https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/rmd-20251231.htm
10-K (2025-08-08) https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm
10-K (2024-08-09) https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/rmd-20240630.htm

Other sources

[news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
[news] ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
[news] Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
[news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
[news] ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
[news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
[news] Is ResMed Inc (RMD) a Bargain After 6.3% Drop? GF Value Says Und - GuruFocus
[news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
[news] ResMed stock held at Hold by Needham as MatrixCare sale announced - Investing.com
[news] ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion - ChartMill
[news] ResMed (NYSE: RMD) counsel surrenders shares for RSU tax withholding - Stock Titan
[news] Is It Too Late to Buy ResMed Inc (RMD) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
[news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
[news] ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance
[news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
[news] Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026 - Moomoo
[news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
[news] BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
[news] ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
[news] Is This the Right Time to Retain Resmed Stock in Your Portfolio? - TradingView
[news] ResMed Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
[news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
[news] ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
[news] Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues? - Yahoo Finance
[news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
[news] Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
[news] ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
[news] Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Yahoo Finance
[news] Is ResMed Stock Underperforming the Dow? - Yahoo Finance
[news] ResMed Inc (RMD) Shares Surge 4.2% -- What GF Score of 90 Tells Investors - GuruFocus
[news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
[news] Resmed Inc (RMD) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
[news] ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
[news] Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
[news] ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case - TIKR.com
[news] Enterprise value to EBIT forward of ResMed Inc. – NYSE:RMD - TradingView
[news] Price to earnings forward of ResMed Inc. – NYSE:RMD - TradingView
[news] RMD|Resmed Inc|Price:195.270|Chg%:+3.440 - TradingKey
[news] Resmed Inc (RMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[news] ResMed Inc. (RMD) Stock Analysis: Unveiling A 39% Potential Upside Amidst Solid Growth - DirectorsTalk Interviews
[news] ResMed Inc. stock falls Monday, underperforms market - MarketWatch
[news] Why Resmed (RMD) Stock Is Up Today - Moomoo
[news] ResMed (RMD) slides as shares hit a 52-week low amid renewed post-earnings scrutiny | RMD Stock News - Quiver Quantitative
[news] ResMed Inc (RMD) Stock Down 6.3% -- Now Undervalued? GF Score: 9 - GuruFocus
[news] ResMed Inc. stock falls Friday, underperforms market - MarketWatch
[news] ResMed Inc. stock rises Friday, outperforms market - MarketWatch
[news] Resmed Inc (RMD) Earnings Dates, Call Summary & Reports - TipRanks
[news] ResMed Inc. stock falls Friday, underperforms market - MarketWatch
[news] Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
[news] ResMed Inc. stock falls Friday, underperforms market - MarketWatch
[news] Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
[news] ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
[news] ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook - Sahm
[news] Why ResMed (RMD) Stock Is Trading Up Today - Yahoo Finance
[discussion] [Bullish] As a digital health pioneer scaling out-of-hospital software solutions and sleep apnea tre
[discussion] @theresilienttrader this company is dead until they make a move to expand beyond machines. GLP-1&#39
[discussion] [Bearish] $RMD

After digging into ResMed ($RMD), I think the market may be underestimating one stru

[discussion] [Bullish] @4nJoy @HANR @uscdal32 "You just pulled the golden thread of this entire M&A arch
[discussion] [Bullish] $RMD opened a long position
[discussion] The broader market maintains historically elevated metrics, with the S&P 500 average P/E ratio t
[discussion] [Bullish] $IXHL $RMD still find this interesting given Goldman Sachs continued presence on the L2…ht
[discussion] $RMD Apnimed IPO could be happening soon. It’s getting closer.
[discussion] Doubled $MSFT and $NVDA positions today.

Started $PODD and $RMD

[discussion] $RMD Jefferies cuts target price to $225 from $240
[discussion] [Bullish] $IXHL Three choices, $RMD buy before DReAMzz, pay 3× after, or risk losing it to someone l
[discussion] Relative Volume Scanner Highlights for 7/6. Capital continues to rotate heavily into Health Technolo
[discussion] $RMD ResMed added to APAC Conviction List at Goldman Sachs

Goldman Sachs analysts added ResMed to

[discussion] $RMD Current Stock Price: $198.47 Contracts to trade: $200.0 RMD Jul 17 2026 Call Entry: $2.95 Exit:
[discussion] $RMD Current Stock Price: $189.04 Contracts to trade: $190.0 RMD Jul 17 2026 Call Entry: $5.40 Exit:
[discussion] $RMD Morgan Stanley killed it … but it is true that Philips Respironics will likely be back in 2027
[discussion] $RMD https://anachart.com/wp-content/uploads/2026/06/1781704878_soc-img.jpg
[discussion] $FIG $LZB $REXR $RMD $SPCX not helpful
[discussion] Pre-Market Fly By for Wednesday, June 17th: Breaking Stock Market News $SPCX $LZB $RMD $REXR $FIG
[discussion] $RMD | Morgan Stanley Downgrades ResMed to Equalweight with $230 PT on Margin Pressures and Competit
[discussion] ResMed just downgraded at Morgan Stanley, here's why - $RMD - https://thefly.com/RMD
[discussion] $RMD whether reality or not, the retatrutide news from Lilly is going to put a lid on ResMed with t
[discussion] [Bullish] $LLY Bye bye $RMD
[discussion] $RMD hopefully clears 200 today and stays there. On the numbers, it should not in any case be less
[discussion] $RMD started position at 198.43
[discussion] $RMD belongs back over $200 … maybe soon

Data gaps

Dataset completeness: 80 of 80 source documents were dropped to fit the prompt budget — the council did not see them.

Generated 2026-07-27T07:06:44 · est. cost $0.77

What each investor thinks

Chuck Akre Quality

pass · 78

Warren Buffett Quality

pass · 78

Valuation Referee (Damodaran-style) Referee

pass · 78

Charlie Munger Quality

pass · 78

Terry Smith (Fundsmith) Quality

pass · 78

Joel Greenblatt Value

pass · 76

Philip Fisher Growth

pass · 74

Bruce Greenwald Value

pass · 74

Michael Mauboussin Quality

pass · 74

Ray Dalio Risk

pass · 72

AI & Disruption Referee (Christensen-style) Referee

pass · 72

Forensic Short-Seller (Chanos/Einhorn-style) Referee

pass · 72

Peter Lynch Growth

watch · 58

Seth Klarman Value

watch · 55

Howard Marks Risk

watch · 55

Stanley Druckenmiller Risk

watch · 52

Benjamin Graham Value

watch · 52

Walter Schloss Value

avoid · 22

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →

Resmed Inc

RESMED INC (RMD) — Council Assessment

🟢 PASS · Score 72/100 · medium confidence

360 narrative — news & sentiment digest

ResMed Inc. (RMD) — Investment Briefing

Recent Developments

Bull Narrative

Bear Narrative

Management Commentary (Earnings Call)

Retail Sentiment

Caveats

Bull case

Bear case

Dissent — where the council disagrees

Key risks

Catalysts

DCF valuation (finance-expert model)

Short-sell evaluation

Council scorecard

Member reasoning

Chuck Akre — 🟢 pass · 78/100 · medium confidence

Warren Buffett — 🟢 pass · 78/100 · medium confidence

Valuation Referee (Damodaran-style) — 🟢 pass · 78/100 · high confidence

Charlie Munger — 🟢 pass · 78/100 · medium confidence

Terry Smith (Fundsmith) — 🟢 pass · 78/100 · medium confidence

Joel Greenblatt — 🟢 pass · 76/100 · medium confidence

Philip Fisher — 🟢 pass · 74/100 · medium confidence

Bruce Greenwald — 🟢 pass · 74/100 · medium confidence

Michael Mauboussin — 🟢 pass · 74/100 · medium confidence

Ray Dalio — 🟢 pass · 72/100 · medium confidence

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 72/100 · medium confidence

Peter Lynch — 🟡 watch · 58/100 · medium confidence

Seth Klarman — 🟡 watch · 55/100 · medium confidence

Howard Marks — 🟡 watch · 55/100 · medium confidence

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

Walter Schloss — 🔴 avoid · 22/100 · high confidence

Fact base appendix

Chuck Akre Quality

Warren Buffett Quality

Valuation Referee (Damodaran-style) Referee

Charlie Munger Quality

Terry Smith (Fundsmith) Quality

Joel Greenblatt Value

Philip Fisher Growth

Bruce Greenwald Value

Michael Mauboussin Quality

Ray Dalio Risk

AI & Disruption Referee (Christensen-style) Referee

Forensic Short-Seller (Chanos/Einhorn-style) Referee

Peter Lynch Growth

Seth Klarman Value

Howard Marks Risk

Stanley Druckenmiller Risk

Benjamin Graham Value

Walter Schloss Value